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ABSTRACT 
Objectives: to assess the value of quantitative vascular imaging by power Doppler 
ultrasound (PDUS) as a tool that can be used to stratify patient risk of joint damage 
in early seropositive RA while still biologic-naive but on synthetic DMARD treatment. 
Methods: 85 patients with seropositive RA <3 years duration, had clinical, laboratory 
and imaging assessments at 0, 6 and 12 months. Imaging assessments consisted of 
radiographs of hands and feet, 2 dimensional high frequency and PDUS imaging of 
10 metacarpophalangeal joints (MCPJs) which were scored for erosions and 
vascularity, and 3 dimensional PDUS of MCPJs and wrists which were scored for 
vascularity.  
Results: Severe deterioration on radiographs and ultrasonography was seen in 45% 
and 28% of patients respectively. 3D PD volume and 2D vascularity scores were the 
most useful ultrasound predictors of deterioration. These variables were modelled in 
2 equations which estimate structural damage over 12 months. The equations had a 
sensitivity of 63.2% and specificity of 80.9% for predicting structural damage on x-
ray, and a sensitivity of 54.2% and specificity of 96.7% for predicting structural 
damage on ultrasound. 
Conclusions: In seropositive early RA, quantitative vascular imaging by PDUS has 
clinical utility in predicting which patients would derive benefit from early use of 
biologics therapy. 
 
 
4	  
	  
TABLE OF CONTENTS              PAGE 
 
DECLARATION OF ORIGINALITY       2 
COPYRIGHT DECLARATION        2 
ABSTRACT           3 
LIST OF FIGURES          7 
LIST OF TABLES          9 
ABBREVIATIONS          11 
CHAPTER1. INTRODUCTION        14 
1.1  Current Concepts in Treatment of Rheumatoid Arthritis   14 
1.2  Why is it Important to predict the course of Disease   23 
1.3  Biology of Rheumatoid Arthritis:        
Angiogenesis and Vascularity       24 
1.4 Methods of Evaluating Disease Activity     27 
 1.4.1. Clinical Quantitative Joint Assessments    28 
 1.4.2. Health Assessment Questionnaire     32 
 1.4.3. Multidimensional Assessment of Fatigue    33 
1.5 Biomarkers         33 
 1.5.1. Inflammatory Markers      34 
5	  
	  
 1.5.2. Autoantibodies       36 
 1.5.3. Genetic Markers       40 
1.6. Imaging in Rheumatoid Arthritis      44 
 1.6.1. Conventional Radiography      44 
 1.6.2. Magnetic Resonance Imaging     49 
 1.6.3. Ultrasonography       50 
CHAPTER 2. METHODOLOGY        57 
2.1 Patients          57 
 2.2 Clinical Assessment        58 
 2.3 Radiographic Evaluation       59 
 2.4 Laboratory Assessments       59 
 2.5 Power Doppler and Grey Scale Ultrasonography    60 
 2.6 Method of Analysis: Ultrasonography     64 
  2.6.1. Two Dimensional Imaging      64 
  2.6.2. Erosion Detection       70 
  2.6.3. Three Dimensional Imaging     72 
 2.7 Method of Analysis: Radiographic Scoring     84 
 2.8 Statistical analysis        88 
CHAPTER 3. RESULTS         89 
6	  
	  
 3.1 Descriptive Statistics        89 
  3.1.1. Patient Characteristics      90 
  3.1.2. Clinical Characteristics      90 
  3.1.3. Ultrasound Results       92 
  3.1.4. Radiographic Results      93 
 3.2 Raw Data Analysis        93 
 3.3 Statistical Methodology       99 
  3.3.1. Radiographic Progression (VdH Score)             103 
  3.3.2. Ultrasound Progression               103 
 3.4 Reliability Analysis                 110 
  3.4.1. 2D Reliability                 110 
  3.4.2. 3D Reliability                 115 
CHAPTER 4. CONCLUDING DISCUSSION               117 
 4.1 Discussion                  117 
 4.2 Future Direction                  127 
 REFERENCES                   129 
 
 
7	  
	  
LIST OF FIGURES            PAGE 
1.1 Individual progression scores of 135 rheumatoid arthritis patients who 
participated in the COBRA trial       17 
2.1 Normal 2D MCP joint        65 
2.2 VdH Modification of Sharp Score       86 
3.1 Correlation of progression of erosions on ultrasound with baseline MCP  
3D power Doppler volume        95 
3.2 Correlations between change in VdH Sharp score at 12 months and 
 vascular markers at baseline       97 
3.3 Correlations between change in VdH Sharp score at 12 months and 
 vascular markers at baseline       97 
3.4 Correlations between change in VdH Sharp score at 12 months and  
baseline CRP and disease activity score      98 
3.5 Correlations between change in VdH Sharp score at 12 months and  
baseline CRP and disease activity score      98 
3.6 Scatterplot of change in VdH score against 3D MCPJ Power Doppler  
Volume                   105 
 
8	  
	  
3.7 Scatterplot of change in ultrasound erosions score against 3D  
Power Doppler Volume at MCPJs                105 
3.8 Intra-class correlation for 2D ultrasound scores              111 
3.9 Intra class correlation for 3D power Doppler volume             115 
 
 
 
 
 
 
 
 
 
 
 
 
 
9	  
	  
LIST OF TABLES            PAGE 
1.1 The American Rheumatism Association 1987 revised criteria for the 
classification of rheumatoid arthritis      19 
1.2 The 2010 ACR-EULAR classification criteria for rheumatoid arthritis  21 
1.3 Comparison of joints included in various standard joint counts  30 
1.4 A comparison of common radiographic scoring systems used in  
rheumatoid arthritis         48 
2.1 Study Schedule         61 
3.1 Summary of primary outcome variables      89 
3.2 Summary of other independent variables at baseline    91 
3.3 Ultrasound erosions by location       92 
3.4 Correlation of progression of erosions on ultrasound with baseline  
parameters          94 
3.5 Correlation of progression of VdH score with baseline parameters  96 
3.6 Variables included in the analysis               100 
3.7 Results of bivariate analysis: correlation between radiographic /  
ultrasound progression and ultrasound variables measured at baseline 
 visit                    104 
10	  
	  
3.8 Exploratory multivariate analysis: linear regression of RA progression 
 against two ultrasound variables and one other explanatory variable         106 
3.9 Multivariate analysis of RA progression against ultrasound and other  
variables carried forward from exploratory analyses             108 
3.10 Model equations, sensitivity and specificity of selected “final” models         110 
4.1 Studies investigating prediction of progression of joint erosions in           128 
patients with rheumatoid arthritis (RA) using baseline imaging parameters. 
 
 
 
 
 
 
 
 
 
 
 
11	  
	  
ABBREVIATIONS 
	  
ACR   American College of Rheumatology 
AE   Adverse Event 
ALP   Alkaline phosphatase 
ALT   Alanine aminotransferase 
AST   Aspartate aminotransferase 
AUC   Area under the curve 
BP   Blood pressure 
CIB/IB  Clinical Investigator's Brochure/Investigator's Brochure 
 
CCP  Cyclic Citrullinated Peptide 
 
CK   Creatine kinase 
CR   Conventional Radiography 
CRF   Case Report Form 
CRP   C-reactive protein 
DAS   Disease Activity Score 
DMARD  Disease Modifying Anti-Rheumatic Drug 
DNA   Deoxyribonucleic acid 
ECG   Electrocardiogram 
EDTA   Ethylene diamine tetra acetate 
EISR   Expedited Investigator Safety Report 
ELISA   Enzyme-Linked Immunosorbent Assay 
ESR   Erythrocyte sedimentation rate 
12	  
	  
EULAR  European League against Rheumatism 
GCP   Good Clinical Practice 
GFR   Glomerular filtration rate 
HAQ   Health Assessment Questionnaire 
HFUS   High Frequency Ultra Sound 
IL   Interleukin 
LFT   Liver function test 
MCP   Metacarpophalangeal 
MCV   Mean corpuscular volume 
MCH   Mean corpuscular hemoglobin 
MCHC   Mean corpuscular hemoglobin concentration  
Mg   Milligram 
Ml   Millilitre 
MMP   Matrix Metalloproteinase 
MRI   Magnetic Resonance Imaging 
MRNA   Messenger ribonucleic acid 
MSDS   Material safety data sheet 
MTX   Methotrexate 
NO   Nitric Oxide 
NSAID   Non Steroidal Anti-Inflammatory Drug 
OA   Osteoarthritis 
PCR   Polymerase Chain Reaction 
PDUS   Power Doppler Ultra Sound 
13	  
	  
QC   Quality control 
RA   Rheumatoid Arthritis 
RANTES Regulated upon activation, normal T-cell expressed and 
secreted 
RESE   Rates of early Synovial Enhancement 
RBC   Red blood cell 
RF   Rheumatoid factor 
SAE   Serious adverse event 
SF   Synovial fluid 
SJC   Swollen joint count 
SRM   Study reference manual 
TGFβ   Transforming Growth Factor Beta 
TIMP   Tissue Inhibitor of Metalloproteinases 
TJC   Tender joint count 
TNFα   Tumour Necrosis Factor alpha 
TNFSF  Tumour Necrosis Factor ligand Super Family 
ULN   Upper limit of normal 
VAS   Visual Analogue Scale 
VEGF   Vascular Endothelial Growth Factor 
WBC   White blood cell 
 
14	  
	  
1. INTRODUCTION 
1.1. Current concepts in treatment of Rheumatoid Arthritis 
	  
Rheumatoid arthritis (RA) is a clinical syndrome with a prevalence of 0.5-1% in 
developed countries [1]. It is characterized by joint swelling, joint tenderness, and 
erosion of cartilage and bone which leads to the destruction of synovial joints. Given 
the presence of autoantibodies, such as rheumatoid factor (RF) and anti–citrullinated 
protein antibody (ACPA) (tested as anti–cyclic citrullinated peptide [anti-CCP]), which 
can precede the clinical manifestation of RA by many years, RA is considered an 
autoimmune disease [2]. 
 
Joint damage and disability both increase throughout the duration of treated RA. 
Scott et al reported that joint damage progresses constantly over the first 20 years of 
RA and accounts for 25% of disability in established RA [3]. They pointed to a strong 
and probably causal link between joint damage and subsequent disability indicating 
that radiographic damage is a major determinant of long term physical function in 
established RA. A more recent analysis [4] also provides further evidence for the 
longitudinal relationship between progression of radiographic damage, even at low 
levels and over short periods of time, and worsening physical function. Other studies 
point to an interplay between disease activity and joint damage affecting functional 
capacity which may vary depending on the phase of disease, with disease activity 
being the main determinant of functional capacity early in the disease and joint 
destruction later in the disease course [5,6]. Aletaha et al have shown that reduction 
in functional disability is greatest when overall disease activity is effectively reduced - 
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in states of clinical remission functional activity normalises in those without joint 
damage, whereas in patients with joint destruction, residual disability is primarily 
governed by the joint damage accumulated thus far [7]. Even modest disease activity 
over time may lead to functional loss, with a study by Conaghan et al reporting  that 
both high and moderate disease activity in early RA is associated with functional 
decline. Therefore curtailing disease activity and avoiding or reducing joint damage 
in both early and late RA is likely to maintain function [8]. This is important since 
reports of clinical cohorts indicate that work disability remains a major problem in RA 
and that physical function and radiographic erosions are significant identifiers of work 
disability [9]. However, although at cohort level radiographic progression is linear 
over time, this is not always the case in individual patients [10] where fluctuations in 
disease activity are directly related to changes in radiologic progression, particularly 
in seropositive patients. In addition, in most clinical studies, radiographic progression 
at a cohort level is typically presented by descriptive statistics such as medians and 
percentiles combined with means and standard deviations which can give rise to a 
loss of potentially relevant information [11] and gives the appearance of linear 
progression over time. However, with the use of cumulative probability plots of 
structural damage progression,	  as a means of presenting radiographic progression 
scores, it can be seen that this progression is actually driven by a small proportion of 
patients (see figure 1). More challenging is that this proportion of patients who 
experience radiographic progression is actually declining,	  and in trials, the damage 
rate is about 5-fold less in 2005 than it was in 1997 [12]. In part this is because of the 
revised approach to the treatment of patients with RA over the past decade, which 
includes early recognition of RA and early DMARD instigation, as well as an 
increasing number of treatment options [12]. Contemporary pharmacotherapeutic 
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interventions are potently disease modifying and indeed may completely abrogate 
damage progression but do not reverse established damage. For these reasons, 
there is a need for a clinical tool which will identify the subpopulation of patients with 
early RA who will progress. 
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Figure 1.1: Individual progression scores of 135 rheumatoid arthritis patients who participated in 
the COBRA trial (Boers M et al. Randomised comparison of combined step-down prednisolone, 
methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 
350: 309–18). Data are presented by histogram (A), cumulative probability plot (B), and dot plot (C). 
From Landewe, R.et al.Arthritis & Rheumatism Volume 50, Issue 3, pages 699–706,2004. 
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Until recently, the standard means of defining RA was by use of the 1987 ACR 
classification criteria (see overleaf). These criteria were well accepted as providing a 
benchmark for disease definition, but had a significant limitation in that they were 
derived by trying to discriminate patients who had established RA from patients with 
other rheumatological diagnoses, and were intended for the purpose of defining 
relatively homogenous phenotypic populations for inclusion in clinical trials. As such, 
these criteria were developed based on patients with a mean duration of disease of 
eight years and contain elements associated with disease severity rather than 
disease development, such as the presence of nodules or radiographic erosions. 
They are not therefore helpful in identifying individuals with early disease and those 
who would benefit from early intervention. Indeed recent evidence points to a three 
month window of opportunity to achieve a good therapeutic response; thus patients 
whose disease activity during therapy reaches at least a moderate level within 3 
months are likely to escape high levels of disease activity at one year, i.e: the 
response achieved within the first three months is highly predictive of the degree of 
clinical outcome at one year [7]. A meta-analysis of 12 studies of early versus 
delayed disease modifying therapy found a 33% reduction of radiographic 
progression in RA patients treated early [13]. This analysis supports the idea of a 
window of opportunity for initiating therapy in early RA, which is associated with 
significantly improved long-term outcomes. In addition these results suggest that 
early therapy with disease modifying agents (DMARDS) has a durable effect on the 
rate of radiographic progression of RA up to 5 years after initiation of this therapy. 
Thus over the last decade, the paradigm for management of RA has shifted such 
that the use of the 1987 classification criteria for RA is obsolete in the clinical setting 
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of the presentation of early inflammatory arthritis. The more contemporary emphasis 
on the importance of early treatment intervention in routine clinical practice has led to 
new classification criteria developed in 2010 jointly by the American College of 
Rheumatology and the European League Against Rheumatism (see overleaf). These 
classification criteria for RA present a new approach with a specific emphasis on 
identifying patients with a relatively short duration of symptoms who may benefit from 
early institution of DMARD therapy, or entry into clinical trials of promising new 
agents that may halt the development of disease that currently fulfils the 1987 ACR 
criteria [14]. At the same time, an international task force have published 
recommendations detailing strategies which aim to reach optimal outcomes for 
patients with RA based on evidence and expert opinion [15]. Key among these 
recommendations are the concepts of “tight control” which can be defined as “a 
treatment strategy tailored to the individual patient with RA, which aims to achieve a 
predefined level of low disease activity or remission within a certain period of 
time”[16]; and “treating to target” where the primary target for treatment of 
rheumatoid arthritis should be a state of clinical remission, defined as the absence of 
signs and symptoms of significant inflammatory disease activity. Until the desired 
treatment target is reached, drug therapy should be adjusted at least every 3 months 
[14]. 
 
 
Table 1.1: The American Rheumatism Association (later American College of 
Rheumatology) 1987 revised criteria for the classification of rheumatoid 
arthritis 
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Table 1.2: The 2010 ACR-EULAR classification criteria for rheumatoid arthritis 
 
	   Score 
Target population(who should be tested?): Patients who 
1. Have at least 1 joint with definite clinical synovitis (swelling)* 
2. With the synovitis not better explained by another disease+ 
Classification criteria for RA(score based algorithm: add score of categories A-D 
A score of ≥6/10 is needed for classification of a patient as having definite RA± 
A. Joint involvement ¥ 
1 large joint§ 
2-10 large joints 
1-3 small joints (with or without involvement of large joints)# 
4-10 small joints (with or without involvement of large joints) 
>10 joints (at least 1 small joint)$ 
B. Serology (at least 1 test result is needed for classification)≠ 
Negative RF and negative ACPA 
Low-positive RF or low- positive ACPA 
High- positive RF or high-positive ACPA 
C. Acute phase reactants (at least 1 test result is needed for classification)¶ 
Normal CRP and ESR 
Abnormal CRP or ESR 
D. Duration of symptoms β 
<6 weeks 
≥6 weeks 
 
 
 
 
 
0 
1 
2 
3 
5 
 
0 
2 
3 
 
0 
1 
 
0 
1 
22	  
	  
*The criteria are aimed at classification of newly presenting patients. In addition, patients 
with erosive disease typical of RA with a history compatible with prior fulfilment of the 2010 
criteria should be classified as having RA. Patients with longstanding disease, including 
those whose disease is inactive who...have previously fulfilled the 2010 criteria should be 
classified as having RA. 
+Differential diagnoses vary but may include conditions such as systemic lupus 
erythematosis, psoriatic arthritis and gout. If it is unclear about the relevant differential 
diagnoses to consider than an expert rheumatologist should be consulted. 
±Although patients with a score of <6/10 are not classifiable as having RA, their status can 
be reassessed and the criteria might be fulfilled cumulatively over time. 
¥Joint involvement refers to any swollen or tender joint on examination, which may be 
confirmed by imaging evidence of synovitis. Distal interphalangeal joints, first 
carpometacarpal joints and first metatarsophalangeal joints are excluded from assessment. 
Categories of joint distribution are classified according to the location and number of 
involved joints, with placement into the highest category possible based on the pattern of 
joint involvement. 
§Large joints refers to the shoulders, elbows, hips, knees and ankles 
#Small joints refers to the metacarpophalangeal joints, proximal interphalangeal joints, 
second through fifth metatarsophalangeal joints, thumb interphalangeal joints and wrists. 
$In this category, at least 1 of the involved joints must be a small joint, the other joints can 
be a combination of large and additional small joints, as well as joints not specifically listed 
elsewhere (e.g: temporomandibular, acromioclavicular etc.) 
≠Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) 
for the laboratory and assay, low-positive refers to IU values that are higher than the ULN 
but ≤3 times the ULN for the laboratory and assay, high-positive refers to IU values that are 
>3 times the ULN for the laboratory and assay. Where rheumatoid factor (RF) information is 
only available as a positive or negative, a positive result should be scored as low-positive for 
RF. ACPA = anti-citrullinated protein antibody. 
¶Normal/abnormal is determined by local laboratory standards. CRP=C reactive protein, 
ESR= erythrocyte sedimentation rate. 
β Duration of symptoms refers to patient self report of the duration of signs or symptoms of 
synovitis (e.g: pain, swelling, tenderness) of joints that are clinically involved at the time of 
assessment, regardless of the treatment status. 
Aletaha D. et al; 2010 Rheumatoid Arthritis Classification Criteria; Arthritis Rheum.Vol 62, N0 
9, September 2010, pp 2569-2581 
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1.2.  Why is it important to predict the course of disease?  
	  
The severity of disease varies between patients, both in the extent and pattern of 
joint involvement and also the rate of progression of erosions.  The disease course 
of persons who meet criteria for classification of RA may vary greatly from self-
limiting to progressive erosive disabling forms.  
 
Reducing joint damage in both early and late RA is achievable by pharmacological 
means. Current treatments include steroids, non-steroidal anti-inflammatory drugs 
(NSAIDs), disease modifying antirheumatic drugs (DMARDs) which include 
conventional synthetic drugs (cDMARDS) and protein based “biologic” therapies with 
specificity for extracellular or cell surface pathogenic molecules such as Tumour 
Necrosis Factor (the inhibitors of tumour necrosis factor α). Also a newer generation 
of small molecular, synthetic DMARDs in development target intracellular pathogenic 
molecules such as kinase enzymes. Biologic therapies have been utilized mostly in 
patients with established disease who remain active despite multiple DMARD use. 
Taken alone or in combination with DMARDs they have had a major impact by 
improving the functional status of patients and further reducing progression in 
radiographic disease [17,18]. In the UK, in accordance with the current guidelines, 
only those patients with established disease who have continuing high levels of 
disease activity, despite multiple DMARD therapies are candidates for anti-TNFα 
therapy (National Institute of Clinical Excellence guidelines).The difficulty with this 
form of rationing is that a significant proportion of patients with lower levels of 
disease activity continue to accrue structural damage to joints with consequent loss 
of function over time.  Furthermore, TNF α inhibitors are generally not available at 
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the earliest stages of disease where there is the highest potential to prevent joint 
damage, and subsequent disability, despite clear evidence of such benefits in study 
populations and preliminary data suggesting that early treatment with an anti-TNFα 
agent may permit induction of biologic-free remission [19]. Cost-effective and optimal 
clinical use of expensive biologic agents is further complicated by the fact that a 
significant proportion of RA patients are refractory to TNFα blockade, suggesting that 
other pro-inflammatory molecules or immunological pathways drive the clinical 
syndrome in this population. In a long term, large scale study of RA patients based in 
the USA, biological therapy was seen to retard progression of arthritis, however it’s 
clinical and cost effectiveness was far less than that seen in clinical trials. This 
probably reflects the non-selective nature of biologic prescribing in this population 
where only a minority of patients had severe disease prior to starting anti-TNFα 
therapy [20]. Thus the ability to identify patients who will develop marked structural 
damage while on synthetic DMARDs would inform a decision to treat with biologic 
therapy and we could tailor treatment on an individual patient basis.  
The patient’s treatment could then be adapted according to their risk thereby more 
effectively preventing or retarding further erosions as well as avoiding the use of 
unnecessary treatments.  
 
1.3. Biology of Rheumatoid arthritis: Angiogenesis and 
Vascularity 
 
Rheumatoid arthritis is characterized by the presence of synovial inflammation and 
proliferation, which if unchecked leads to cartilage and bone erosion with eventual 
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joint damage. Maintenance and growth of the proliferating synovial mass requires 
the formation of new blood vessels which deliver nutrients to the proliferating tissue 
and may also facilitate the recruitment of inflammatory cells to the synovium via 
transendothelial migration. Neovascularisation of the synovium in the joints of RA 
patients is considered by some investigators to be an important early step in the 
pathogenesis of RA [21], and may contribute toward the formation of erosions and 
structural joint damage in arthritis. 
 
Angiogenesis is defined as the development of new blood vessels from pre existing 
vasculature. It starts with endothelial cell (EC) activation by angiogenic stimulus 
which leads to breakdown of the basement membrane and extracellular matrix. The 
ECs then migrate forming primitive angiotubes which then mature - acquiring a 
lumen, pericyte layer and reconstruction of the basement membrane. This occurs as 
a normal physiological process during wound healing, embryogenesis and the 
female reproductive cycle. It also occurs during pathological processes such as 
tumourogenesis, proliferative retinopathy and chronic inflammatory diseases such as 
rheumatoid arthritis. In arthritis, leucocyte ingress into the synovium occurs by 
leucocyte adhesion to endothelial cells and then transendothelial migration. ECs play 
an active role in inflammation secreting several vasodilating mediators such as nitric 
oxide and prostacyclin. Synovitis is associated with vasodilation, increased vascular 
permeability, vascular injury triggered by pro-inflammatory mediators released 
primarily by activated neutrophils, and finally by endothelial regeneration associated 
with angiogenesis [22]. This was seen in a recent study which demonstrated the 
presence of both immature and mature vessels in the inflamed synovium, with a 
significant proportion of vessels not having recruited supporting pericytes, which are 
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essential for vessel stabilization. This is in contrast to osteoarthritis and normal 
synovial tissue, in which intact pericyte layers were observed and which had a stable 
synovial vasculature. Furthermore, the study demonstrated a direct relationship 
between low oxygen levels in the joint and macroscopic vascularity, microscopic 
vessel number and pericyte recruitment. This implies that in a hypoxic environment, 
synovial vessels are in a constant state of remodelling, and vessels are still in an 
unstable state [23]. 
Hypoxia is one of the key drivers for angiogenesis and is often a feature of 
inflammation. Microelectrode studies have confirmed that synovium in RA patients is 
more hypoxic than normal synovium, with median synovial oxygen tension of 6% 
(46mmHg) and 10% (74mmHg) respectively [24]. Studies have also demonstrated 
decreased glucose levels with raised carbon dioxide, lactate and acetate levels 
within RA synovium, consistent with anaerobic metabolism [25]. This 
microenvironment promotes and upregulates angiogenesis, induced in part by the 
stimulation of hypoxia inducible transcription factor (HIF-1 and HIF-2) production. 
HIF can also be upregulated by inflammatory cytokines and has a major pro-
angiogenic effect via upregulation of Vascular Endothelial Growth Factor (VEGF) 
[23]. VEGF is the most important growth factor involved in angiogenesis and plays 
an active role particularly early on in the proliferation and migration of vascular 
endothelial cells. It is upregulated by proinflammatory cytokines such as TNFα and 
IL1 and also by hypoxia, all of which are present inside the rheumatoid synovium.  
 Other factors such as angiopoietin-1, transforming growth factor β, and platelet 
derived growth factor are also important in the subsequent processes, such as 
acquisition of the pericyte layer, which are needed to induce vessel formation [26]. 
In a study of patients attending an early inflammatory arthritis and established RA 
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clinic, it was found that serum VEGF concentrations were significantly higher in 
patients with inflammatory arthritis than in individuals with osteoarthritis. Levels were 
also higher in early RA patients than in patients with longstanding, treated RA [21]. 
Patients responding to therapy with DMARDs exhibited a significant reduction in 
serum VEGF concentration, in contrast to people unresponsive to DMARDs where 
there was no significant reduction in serum VEGF concentrations. In addition serum 
VEGF concentrations at presentation correlated highly significantly with the 
development of radiographic damage over the subsequent year as assessed by the 
van der Heijde modification of Sharps method [21]. An earlier study described how 
treatment of RA patients with infliximab results in marked reduction of serum VEGF 
concentrations [27]. This reduction correlates with changes in clinical and laboratory 
measures of disease activity. Interestingly, other anti-rheumatic drugs such as 
leflunomide, chloroquine, sulphasalazine and methotrexate inhibit synovial 
angiogenesis by their effect on EC migration [28] and this, as well as the significant 
reductions in serum VEGF levels following response to treatment intervention in RA, 
point to angiogenesis as an important pathogenic process in perpetuation of 
synovitis [29]. This also suggests that measurements of serum VEGF could be a 
useful predictor of disease progression in RA in clinical practice.  
 
1.4 Methods of Evaluating Disease Activity 
	  
There are a variety of methods currently employed to evaluate disease activity in 
clinical practice, this section focuses on clinical measures such as scoring based on 
joint counts, patient reported indices of disease and disability, laboratory markers of 
disease and finally the use of imaging in rheumatoid arthritis. 
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1.4.1 Clinical Quantitative Joint assessments 
Joint counts are widely used both in clinical practice and also in rheumatological 
research. A number of different counts have been developed all of which have the 
evaluation of joint tenderness and swelling as their basis. Joint swelling is defined as 
soft tissue swelling of the joint detectable along the joint margins and the swollen 
joint count reflects the amount of inflamed synovial tissue [30]. Joint tenderness is 
defined as pain at rest that is induced by pressure on examination, and is associated 
more with the level of pain [30].  Counts have been described in many formats with 
66/68 joints evaluated to 28 joint counts, some counts with weighting for degrees of 
tenderness, such as the Ritchie Articular Index, and others non-weighted and more 
simple to administer – these have been summarised by Sokka and Pincus in the 
table overleaf. 
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Joint 66/68 
Joints 
Ritchie 
Index 
44 joints  36 joints  28 joints  42 joints  
Temporomandibular 
Sternoclavicular 
Acromioclavicular 
Shoulder 
Elbow 
Wrist 
Metacarpophalangeal 
 First 
 Second 
 Third 
 Fourth 
 Fifth 
Proximal interphalangeal 
 First 
 Second 
 Third 
 Fourth 
 Fifth 
Distal Interphalangeal 
 Second 
 Third 
 Fourth 
 Fifth 
Hip 
Knee 
Ankle 
Talocalcaneal 
Tarsus 
Metatarsophalangeal 
 First 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+# 
+ 
+ 
 
+ 
 
+ 
+* 
+* 
+* 
+ 
+ 
+ 
+ 
 
 
 
 
 
+ 
 
 
 
 
 
 
 
 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
 
 
 
+ 
+ 
 
 
 
+ 
 
 
 
 
+ 
+ 
 
 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
 
 
 
+ 
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 Second 
 Third 
 Fourth 
 Fifth 
Proximal interphalangeal(toe) 
 First 
 Second 
 Third 
 Fourth 
 Fifth 
 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
 
 
 
 
# assessed for tenderness only; *right and left joints assessed together 
 Table 1.3: Comparison of joints included in various standard joint counts, 
from Sokka and Pincus 
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The Disease Activity Score (DAS) is a clinical index of RA activity that combines 
information from swollen joints, tender joints, the acute phase response and a score 
of general wellbeing [32]. It was developed on the basis of a large prospective trial in 
which the decision of rheumatologists to start a DMARD or to stop such treatment 
because of disease remission were equated with high and low disease activity 
respectively [32]. Various statistical methods including multiple regression analysis 
were used to identify the clinical and laboratory variables which explained most of 
the variance in the rheumatologists’ decision making with regard to clinical 
management. Based on these results the DAS in its original format was composed 
using the Ritchie score, number of swollen joints out of 44, ESR and patient’s global 
assessment. The DAS showed greater discriminant function than other variables in 
discriminating high from low disease activity, and furthermore correlated well with 
increased joint damage over time [33].  
Although well validated, the DAS can be time consuming to perform and thus the 
DAS 28 was developed using the same cohort of patients. It was concluded that 
there was no loss of discriminant function or validity by using reduced, non-weighted 
joint counts. Both the DAS and DAS 28 are utilised in the EULAR response criteria 
which classify patients as good, moderate or non-responders, using the individual 
amount of change in DAS and the DAS value reached [31].  
Although widely utilised and well validated, joint counts, as with all measures, have 
their limitations. Their accuracy depends on the training and experience of the 
assessor and reproducibility of joint counts can be variable. Joint inflammation can 
also be undetectable on palpation, as seen in studies where histologic features of 
synovitis have been found in clinically uninvolved joints of patients with RA [34,35]. 
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Ultimately, although thought of as objective, the joint count can only be regarded as 
a surrogate of inflammation within the joint [30] 
. 
1.4.2 Health Assessment Questionnaire 
Maintenance of good functional capacity is the main goal of RA treatment and as 
such, instruments that allow useful assessment of patient’s functional capacity have 
been developed. The most widely utilised since its inception in 1980 is the Health 
Assessment Questionnaire (HAQ) in its 2 page form (also known as the HAQ-DI or 
Health Assessment Questionnaire disability index) [35].The HAQ-DI includes 20 
items in 8 categories which represent a comprehensive set of functional activities 
such as dressing, walking, rising, eating, hygiene, reach, grip and usual activities. 
For each item there is a four level response set that is scored from 0 to 3, with higher 
scores reflecting increased disability (0 = without any difficulty; 1 = with some 
difficulty; 2 = with much difficulty; 3 = unable to do). The category score is the 
highest score from the sub category questions, with scores of 0 or 1 increased to 2, if 
aids or devices are used for that particular category. The category scores are then 
averaged into an overall HAQ score from 0 – 3 [37]. Scores up to 1 generally 
represent mild to moderate disability, scores of 1-2 moderate to severe disability, 
and scores of 2-3 severe and very severe disability. 
The HAQ has also been found to be closely related to healthcare resource utilisation 
and also has a strong correlation with changes in employment status and 
absenteeism [36,38]. 
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Relatively high HAQ scores are often found in early RA which reflect disability from 
pain and inflammation. By 5-8 years or longer, HAQ scores and radiographic 
damage are significantly correlated, reflecting disability in part due to joint damage. 
However this relationship is not always linear or consistent and can be confounded 
by demographic factors such as gender, socioeconomic and employment status, 
measures of disease activity and the use of disease modifying drugs [3]. 
 
1.4.3. Multidimensional Assessment of Fatigue (MAF) 
The MAF was originally developed by Belza in 1991 and is a validated, self-reported 
questionnaire consisting of a sixteen item scale that measures fatigue according to 
four dimensions. These dimensions include degree and severity of fatigue, distress 
that it causes, timing of fatigue (over the past week, when it occurred and any 
changes), and its impact on various activities of daily living (household chores, 
cooking, bathing, dressing, working, socializing, sexual activity, leisure and 
recreation, shopping, walking and exercising). Its original purpose was to evaluate 
self-reported fatigue in patients with rheumatoid arthritis [39] but has since been 
used in other populations including people with human immunodeficiency virus 
(HIV), multiple sclerosis (MS), ankylosing spondylitis and various cancers [40]. 
  
1.5  Biomarkers 
Biomarkers can be considered as measurable characteristics which can indicate 
normal biologic processes, pathogenic processes, or responses to therapy.  
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Rheumatoid arthritis is a heterogeneous disease with a variable course both in terms 
of radiological and functional outcome. Early identification of RA patients likely to 
develop erosive disabling disease may allow better control of RA with use of early, 
aggressive medical intervention. This awareness has prompted the investigation into 
various biologic markers for disease susceptibility, severity, progression and 
response to therapy.  
There are several types of biological marker that are currently used in assessing 
various aspects of disease: 
• Markers of the inflammatory process 
• Disease associated autoantibodies 
• Genetic markers 
 
1.5.1  Inflammatory Markers 
	  
Erythrocyte Sedimentation Rate (ESR) 
The most frequently used laboratory markers of disease activity in the clinical setting 
are the inflammatory markers ESR and CRP. Both of these markers have been 
incorporated into commonly used disease activity scoring systems. The ESR tends 
to reflect disease activity over the preceding few weeks, while CRP is reflective of 
more short term changes in disease activity [41]. The ESR is the rate at which 
erythrocytes fall through plasma and can be influenced by a number of factors such 
as gender, age, levels of fibrinogen, anaemia or hypergammaglobulinaemia. Despite 
these limitations, an elevated baseline ESR in patients with early RA has been found 
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to be predictive of radiological joint damage over subsequent years in several 
studies [42,43]. 
C Reactive Protein (CRP) 
C Reactive Protein is one of a group of proteins, called acute phase proteins, which 
are synthesised by hepatocytes during the inflammatory process. This synthesis is 
largely driven by the production of cytokines IL-6, IL-1 and TNF alpha by monocytes, 
macrophages and a variety of other cells. 
 It is recognised that patients with active RA have the most erosive damage. CRP is 
a good measure of disease activity and has been known to predict erosive damage, 
irrespective of the presence or absence of rheumatoid factor [44]. Unlike ESR it is 
independent of age and gender of the patient, is not influenced by haemoglobin 
concentration or the levels of other plasma components such as immunoglobulins, 
and can be measured using stored serum samples.  
It has been established that there are individual relationships between CRP and the 
progression of radiological damage. A group of 110 newly diagnosed patients with 
RA were analysed for a follow-up period of at least three years. A highly significant 
correlation was found between CRP production and radiological progression; 
however, a wide variation was observed due to inter-individual differences: Time-
integrated CRP values correlated closely with radiological progression in each 
patient, but there was considerable variation between individuals with similar 
radiographic scores [45, 46]. 
Further research has provided evidence that early aggressive drug treatment to 
control the CRP reduces radiographic progression [47].  A prospective follow-up 
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study with an experimental group and historical controls were divided into high-risk 
and low-risk subgroups based on prognostic factors. Overall, 228 consecutive 
patients were investigated with recent-onset RA. After 2 years follow-up, comparing 
the 2 high-risk subgroups showed radiographic progression in the aggressively 
treated cases was significantly lower than in controls. Cumulative CRP values were 
also significantly lower than in the control group [47]. In a more recent prospective 
study undertaken to investigate whether a limited set of laboratory markers at 
baseline provided prognostic information in RA, a cohort of 183 patients with early 
RA were followed up over 10 years.  In this cohort CRP at baseline was a significant 
predictor of joint damage on radiographs of the hands and feet after 10 years, with 
an increase in CRP of 1mg/l at baseline translating into an average increase in 
Larsen score of 0.42 at 10 years [43]. 
Despite these studies, variations in CRP levels between patients with similar 
radiographic scores make it difficult to generalize from initial single CRP values in 
individual cases. Furthermore, not all investigations show a similar relationship. For 
example, one study from Leeds (UK) in which 63 patients with early RA were 
followed up for 6 months, found that high initial CRP levels did not predict the 
persistence of arthritis at 6 months [15]. The conventional view that high CRP levels 
indicate a poor prognosis does not necessarily apply in very early RA.  
 
1.5.2 Autoantibodies 
Autoantibodies are antibodies (immune proteins) formed in response to, and reacting 
against, an antigenic constituent of the individual's own tissues. 
37	  
	  
Rheumatoid factor antibodies 
Determination of the rheumatoid factors (RF) has been the central autoimmune 
laboratory test performed in arthritis patients, playing a critical role in both diagnosis 
and prognostication in RA. The rheumatoid factors (RF) are antibodies directed 
against the Fc portion of the IgG immunoglobulins and are found in 75–80% of 
patients affected by RA. The RF was initially described by Waaler and Rose in 1940 
as an IgM RF, and this is the isotype currently measured in clinical practice, although 
other immunoglobulin types including IgG and IgA have been described. 
The presence of RF in the blood may predate the onset of RA by several years, and 
can have a prognostic value as regards the clinical course of the disease [49].The 
titre of RF may also decrease in response to effective clinical treatment with anti- 
TNFα therapy [50,51]. RA seropositivity, i.e. RA with positive values for the RF, is 
often also associated with a more aggressive form of the disease than seronegative 
RA  [42]. An early study by Van Zeben et al followed up 135 women with RA for a 
mean duration of six years, with yearly clinical, immunological and radiological 
assessment. They concluded that patients with a persistently positive RF test, 
generally had more radiological abnormalities, disease activity and extra-articular 
manifestations with worse functional ability than patients with persistently negative 
RF, or intermittently negative RF [52]. A more recent study by Combe et al which 
followed up a cohort of 191 patients with early RA for a mean of 3 years found that 
among the measures of disease activity at baseline, the ESR, duration of morning 
stiffness and pain scores appeared to be the only factors related to subsequent joint 
damage [42]. 
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However, rheumatoid factors are also present in other diseases, such as some 
connective tissue diseases like Systemic Lupus Erythematosus (SLE) and Sjogren 
Syndrome (SS), as well as infectious diseases such as malaria, rubella and 
tuberculosis. They can also be found at low levels in healthy persons. 
Although there is a stronger association of aggressive disease with rheumatoid 
factors, treatment decisions cannot be based wholly on the presence or absence of 
RF. This is because even within the groups who are either seropositive or 
seronegative there will be a range of different disease courses. It is still extremely 
useful to predict the progression of radiographic damage on an individual patient 
basis in order to tailor their therapy accordingly.     
Anti-CCP Antibodies 
Schellekens et al described that sera from RA patients contain autoantibodies 
specific for RA which bind to antigenic determinants that contain the amino acid 
citrulline, formed by post-translational modification of arginine residues by the 
enzyme peptidyl arginine deiminase. These autoantibodies directed at citrullinated 
peptides may represent sensitive and specific markers for RA. In Schellekens 
original study the anti-CCP ELISA proved to be extremely specific for RA (98%) with 
a moderate sensitivity (48-68%) comparable to IgM RF [53]. Since then the so-called 
anti-cyclic citrullinated peptide, second generation (anti-CCP II) enzyme-linked 
immunosorbent assay has been developed which is thought to have greater 
sensitivity levels for the detection of RA. 
This was illustrated in a meta-analysis of 87 studies in which the pooled sensitivity 
and specificity for the diagnosis of RA were 67% (95% CI 62-72%) and 95% (95% 
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CI, 94-97%) for anti-CCP antibodies, compared to 69% (95% CI 65-73%) and 85% 
(95% CI, 82-88&) for IgM RF. In addition anti-CCP antibody positivity, especially anti-
CCP2, was superior to IgM RF positivity for predicting development of RA and 
radiographic progression [54]. 
Several studies have reported that the presence of anti-CCP antibodies can predate 
the development of rheumatoid arthritis. In a study of 79 RA patients with serum 
samples collected a median of 7.5 years prior to the onset of symptoms, 
approximately half of patients had positivity for IgM-RF and/or anti-CCP antibody 
before the development of RA symptoms [55]. In a second Swedish case-control 
study, 83 individuals with RA were identified as having given blood samples prior to 
the onset of joint symptoms. In these samples, the prevalence of autoantibodies for 
anti-CCP was 33.7% up to 9 years prior to onset of RA, with the frequency of 
antibody increasing significantly over time approaching the onset of symptoms. In 
this study combining the presence of anti-CCP antibodies and the presence of any 
RF isotype resulted in specificities of 100% [49].This was also illustrated by Bas et 
al, whereby specificity for RA of IgM RF and anti-CCP antibody increased to 96%, 
from 90% for anti-CCP antibody alone and 82% for RF alone [56]. Combining anti-
CCP antibody and IgM RF ELISA also gave a high positive predictive value for RA 
and predicted erosive disease at 2 years [53]. 
The presence of anti-CCP antibodies is also associated with increased risk of 
progressive joint damage in early RA [43,56]. In a cohort of 191 patients with early 
RA who were followed up prospectively for five years, there was significantly more 
radiographically apparent joint damage after five years of observation in those with 
detectable anti-CCP antibodies, compared to those who were RF-positive [57]. 
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Interestingly, anti-CCP titres may be modulated in patients undergoing effective 
disease modifying therapy although there is conflicting data published with regard to 
this [47,58].                                                                                                                                                                         
Although more specific for RA than RF, anti-CCP autoantibodies can be found in 
other conditions such as tuberculosis [59] or connective tissue diseases such as 
scleroderma, sjogrens syndrome or polymyositis [60]. Ultimately, the limitation of the 
anti-CCP antibody test is the same as stated above for rheumatoid factor, in that a 
patient’s precise treatment cannot necessarily be planned on the basis of a positive 
or negative test result either at diagnosis or to an even lesser extent during 
established disease.  
 
1.5.3 Genetic Markers 
Since the 1970’s a significant genetic contribution to the development of RA has 
been described [61]. To date, the strongest genetic association has been located to 
the HLA region, with the HLA-DRB1 gene in particular, consistently found to be the 
major genetic susceptibility locus for RA. This association becomes better defined in 
the presence of certain DRB1 alleles all of whom share an amino acid sequence 
known as the shared epitope.  
The shared epitope is located along the antigen-binding groove of class II MHC 
molecules, which are responsible for the presentation of antigen to T cells. Class II 
MHC molecules may therefore alter the specific T cells that are positively selected in 
the thymus, thereby leading to a T cell repertoire that could include autoreactive, 
pathogenic T cells. Alternatively, the shared epitope may selectively bind self 
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antigens or exogenous peptides that exhibit molecular mimicry to self and thereby 
initiate an autoimmune inflammatory response [62]. There may also be an important 
gene-environment interaction between the shared epitope and tobacco smoking. A 
recent case-control study showing that smoking, the most well-established 
environmental risk factor for RA, was found to be associated with a 15-fold increased 
risk of RF-positive RA. [63] This link may also hold true for patients with anti-CCP 
antibodies; a Danish study of 515 RA patients and 769 age and sex matched 
population controls found that for individuals who were homozygous for the shared 
epitope, there existed an elevated risk of anti-CCP antibody positive RA, but not anti-
CCP antibody negative RA. The odds ratio for anti-CCP antibody positive RA was 
17.8 (95% CI 11-29). In addition strong combined gene-environment effects were 
observed, with markedly increased risks of anti-CCP antibody positive RA among 
shared epitope homozygotes who were heavy smokers - OR 53 (95% CI 18 - 154) 
[64]. 
It is important to recognize that not all shared epitope alleles confer the same risk for 
development of RA. Weyand et al suggested a hierarchical model of allelic 
combinations which confer different susceptibility for RA [65]. In their study, by far 
the most powerful disease gene appeared to be HLA-DRB1*0401, which has been 
borne out in later studies.  In 2004, Gorman et al in a meta-analysis of 3240 RA 
patients, found that the shared epitope was associated with the development of 
erosive disease in many ethnic groups, with a statistically significant association of 
genotypes containing the HLA-DRB1*0401 shared epitope allele among northern 
european caucasians. Of interest, this association did not appear to be dose 
dependent, with a similar risk in those carrying a single allele versus those carrying 
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two alleles [62]. Fries et al also found that genotypes containing DRB1*0401, unlike 
other shared epitope containing DRB1 alleles, increased susceptibility to RA even if 
only 1 copy of the shared epitope was present. In contrast, DRB1*0404 containing 
genotypes appeared to require 2 copies of the shared epitope in order to increase 
susceptibility to RA. [66] Interestingly, in this study, disability was reduced in those 
patients receiving DMARD treatment irrespective of their genetic status. Similar 
findings were described in an analysis of data from the BeSt study which showed no 
significant association between HLA-DRB1 status and radiographic progression in 
patients with early, active RA who were treated with closely monitored DMARD 
therapies with tight disease control. [67] 
These findings would seem to indicate that adequate treatment of patients’ arthritis 
with DMARD therapy can ameliorate the severity of disease despite patients’ genetic 
status, and thus plays a more important role than genetic risk in the prevention of 
progression of patients’ disease. 
Most estimates of the HLA component of the overall genetic for RA are less than 
50%. Thus interest has turned toward identification of RA associated genes outside 
of the HLA region [68]. Matrix metalloproteinases (MMPs) are a family of zinc-
dependent proteases that are responsible for proteolytic degradation of specific 
extracellular matrix components. MMP-3 is considered to be the main MMP involved 
in cartilage degradation and can contribute toward bone and cartilage destruction in 
RA. A prospective, longitudinal study of 103 patients with early RA supported the 
hypothesis of an association between a polymorphism in the MMP-3 gene promoter 
region and the severity and progression of RA. The MMP-3 6A/6A genotype was 
associated with the highest progression of radiographic joint damage over a four 
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year period whereas the 5A/5A genotype was associated with the lowest [69]. 
IL-10 gene variants may also influence progression of RA. IL-10 is a cytokine 
produced primarily by monocytes, which has pleiotropic effects in immunoregulation 
and inflammation. It stimulates B cell survival, proliferation and differentiation and 
increases autoantibody production by B cells from RA patients. It is also capable of 
inhibiting synthesis of pro-inflammatory cytokines such as TNF-α and IL-1 as well as 
decreasing levels of MMPs produced by macrophages. A study of 283 RA patients 
followed over 2 years found that the IL-10 promoter polymorphism –2849 was 
associated with increased IL-10 production and markedly increased autoantibody 
titres in RA patients. This polymorphism correlated with disease progression, as 
determined by the extent of joint destruction, but was not associated with the 
incidence of RA [70]. 
Given the effectiveness of biologic agents directed against TNF-α in treating RA, 
much research has also been directed at this cytokine, with attempts made at 
identifying genetic markers of severity of and susceptibility to RA. Several Single 
Nucleotide Polymorp hisms (SNPs) involved in the pathway of TNF-α have been 
reported, such as TNF-receptor associated factor (TRAF)1/C5. This encodes a 
protein which mediates signal transduction from various receptors of the TNF 
superfamily including TNF-α. The TRAF-1/C5 SNP showed an increased 
susceptibility to and severity of RA. However further research to confirm these 
findings needs to be undertaken [68]. 
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1.6 Imaging in Rheumatoid Arthritis 
Traditionally in both clinical trials and clinical practice, diagnosis and monitoring of 
disease in patients has relied on the use of conventional radiography. This however 
is far from optimal in evaluating disease and thus interest has turned toward other 
imaging modalities in the hope of finding a more sensitive method for diagnosis, 
monitoring and prognostication of patients, particularly with early RA. 
 
1.6.1 Conventional Radiography 
X-rays are used for all conventional radiography. They are produced by passing a 
very high voltage across two tungsten terminals (the cathode and anode) within an 
evacuated tube. The cathode is heated to liberate free electrons which are attracted 
to the anode when the voltage is applied. X-rays are then produced when the anode 
is struck by the electrons. Radiographic images depend on the fact that x-rays are 
absorbed to a variable extent as they pass through the body; there are four basic 
densities – gas, fat, all other soft tissues and calcified structures. X-rays that pass 
through gas are the least absorbed and thus cause the most blackening of the 
radiograph, whereas calcified structures appear virtually white. Soft tissues and fat 
appear in various shades of grey [71].   
X-ray evaluation of rheumatoid joints is used both to provide an objective measure of 
the extent of anatomical joint damage and to predict further progression. X-ray can 
visualise bone erosions, joint space narrowing as an indirect sign cartilage thinning, 
peri-articular osteoporosis and joint subluxation or ankylosis [72]. It is relatively 
inexpensive, widely available and has standardised methods of interpretation, but 
has many limitations. These limitations include inability to reliably assess soft tissue 
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changes, the use of ionising radiation and projectional superimposition, which can 
obscure erosions and mimic cartilage loss as an inevitable consequence of 
representing a three-dimensional structure in only two planes. Experienced readers 
are required to interpret the films, often using time consuming methods, and 
structural change cannot be reliably determined in less than 6-12 months. 
Conventional radiography offers only late signs of preceding accumulated disease 
activity and the resulting cartilage and bone destruction. This is inadequate because 
ideally we want to take action on the cause of the erosions before they occur. 
Many scoring systems have been developed to quantify radiographic evaluation of 
RA. Most systems selected joints within the hands, wrists and feet as these have 
been found to correlate with total disease burden in other joints and also because 
they have the advantage of being relatively easy to evaluate [73,74]. Two main 
groups of scoring systems exist – global, which assign one score to the entire joint 
taking into account all abnormalities seen, and of which the Larsen score is the most 
commonly used; and detailed, which assign scores on at least two separate 
variables for each joint evaluated. The Sharp method (and its various modifications) 
being the most widely used detailed scoring system [74]. 
In 1971 Sharp et al proposed their original method for scoring radiographic changes 
in RA. Twenty nine areas of the hands and wrists were considered for erosions with 
counts from 0 to 5, giving a total score up to 290. Twenty seven joints were 
considered for joint space narrowing with scores from 0 to 4, allowing a total score 
between 0 and 216 [75]. Over the next thirty plus years, numerous modifications 
have been developed with the two most widely utilised being the Genant modification 
of Sharps method and the Van der Heidje modification of Sharp. The Genant/Sharp 
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method scores selected joints in the hands and feet for erosions and joint space 
narrowing. Erosion scores range from 0 to 3.5 for each joint and joint space 
narrowing is scored from 0 to 4. The total erosion score and total joint score are 
normalised to a scale from 0 to 100, and these two normalised scores are then 
summed to give a joint total [74]. In Van der Heidje’s 1989 modification of Sharp’s 
method, erosion is assessed in 16 joints for each hand and wrist, and 6 joints in each 
foot. One point is scored if erosions are discrete, rising to 2,3,4, or 5, depending on 
the surface area affected, with complete collapse of the bone scored as 5. Thus the 
erosion score in the hands ranges from 0 to 160, and in the feet up to a maximum of 
120 (the maximum erosion score per joint in the foot being 10). Joint space 
narrowing is combined with a score for (sub)luxation as follows: 0 = normal; 1 = focal 
or doubtful; 2 = generalised but less than 50% of original joint space; 3 = generalised 
and greater than 50% of original joint space or subluxation; 4 = bony ankylosis or 
complete luxation [76]. Joint space narrowing is assessed in 15 joints in each hand 
and wrist, and 6 in each foot; the score ranges from 0 to 120 in the hands and 0 to 
48 in the feet. The total Sharp score is generated from the sum of the scores for 
erosion and joint space narrowing.  
The Scott modification of the Larsen method of scoring is the most widely utilised 
global method of scoring joints in RA. In this method, multiple joints in the hands, 
wrists and sometimes feet are evaluated with each joint graded between 0 (normal 
joint) and 5 (mutilating abnormalities) with total scores ranging between 0 and 250 
[77]. 
While the approaches may be different, the radiographic scores obtained by the 
modified Sharp and Larsen methods have been shown to be significantly correlated. 
47	  
	  
Nonetheless, other studies have found that the Sharp method and its variations, 
although potentially more time consuming [78]  are more sensitive, particularly with 
respect to change over time [74]. In a study by Bruynesteyn et al [79] an international 
panel of experts judged that changes in joint damage around the level of the smallest 
detectable difference (5.0) of the Sharp/Van der Heijde method corresponded closely 
with the minimally clinically important difference (defined as the amount of 
progression of radiologic joint damage that makes rheumatologists change 
treatment). However the minimally clinically important difference of the Scott/Larsen 
method was much smaller than its smallest detectable difference, and thus was 
deemed too insensitive to use as a threshold for individual clinically relevant change 
[79]. 
In addition to the type of scoring system used, the way in which radiographs are 
scored and the number of raters used, has a potential to impact on the accuracy and 
reliability of the scores obtained. Several studies have shown that paired reading 
(reading two radiographs from the same patient) is the most suitable for evaluating 
progression of joint damage [78,80,81] and also that reading paired radiographs 
chronologically is more sensitive to change than other approaches, particularly with 
longer follow-up [82].  
The number of assessors reading radiographs also can affect the reliability of 
progression scores: more than one reader reduces measurement error and 
increases precision, however this is at the expense of increased time for training and 
increased cost. The earlier study by Fries et al [81] found that two readers was the 
best compromise. 
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For the purpose of this study described in this thesis, the Van der Heijde modification 
of Sharp score was utilised to evaluate radiographic disease progression. The 
images were evaluated by two raters, reading the films in paired chronological order. 
Table 1.4:  A comparison of common radiographic scoring systems used in 
rheumatoid arthritis 
After Ory 
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1.6.2 Magnetic Resonance Imaging (MRI) 
Since structural change in joints take some months to become evident on 
radiography, other methods of imaging joint structures in inflammatory arthritis have 
been studied in order to enable earlier detection of inflammation and damage. MRI is 
better able to image soft tissue structures in and around joints, as well as detect 
changes in the water content of tissues due to inflammation, infection or ischaemia.  
The basic principles of MRI rely on the fact that the nuclei of certain elements align 
with the magnetic force when placed in a strong magnetic field. In medical imaging, 
hydrogen nuclei (protons) in water molecules and lipids are responsible for 
producing anatomical images. If a radiofrequency pulse at an appropriate frequency 
(resonant frequency) is applied, a proportion of the protons change alignment. 
Following the radiofrequency pulse, the protons return to their original positions. As 
the protons realign they emit a radio signal which can be detected and localised by 
coils placed around the patient. A typical MRI scanner consists of a supercooled 
circular magnet, inside which are the radiofrequency transmitter and receiver coils. 
An image representing the distribution of the hydrogen protons can then be built up 
by ancillary equipment which converts the radio signal into a digital form which is 
then processed by a computer to form a final image [83].   
In early RA, MRI is capable of revealing synovitis and tendonitis as well as bone 
oedema and erosion [84]. Rates of early synovial enhancement (RESE) with MRI of 
the knee have also been shown to correlate closely with histological grade of 
synovitis, with the enhancement rate showing the strongest statistical correlation with 
vessel proliferation and subsynovial infiltration of mononuclear leucocytes [85]. MRI 
imaging has also been shown to be more sensitive than radiography for the 
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detection of erosions at baseline, for the detection of progression of erosions in early 
RA patients, and may be more accurate at detecting active disease in the small 
joints than clinical examination [86]. It has also been suggested that bone oedema 
as seen on MRI is related to the degree of synovitis and is the forerunner of erosions 
[87]. However this finding is not consistent. In a six year prospective study of a 
cohort of patients with RA, baseline bone oedema was found to be significantly 
predictive of erosion at 6 years, however no association between baseline synovitis 
and 6 year erosion was demonstrated, suggesting that the proposed linear causal 
relationship, with synovitis leading to bone oedema in turn leading to erosion, may 
be too simplistic [84]. 
Thus MRI may provide a reproducible method of determining early signs of synovial 
proliferation and joint erosion in RA patients, and thus help predict potentially 
aggressive disease. However the use of MRI is limited by restricted availability and 
high cost. The procedure itself is also time consuming and is unable to be performed 
on certain groups of patients, (those who suffer from claustrophobia or who have 
implanted devices for example). 
 
1.6.3 Ultrasonography  
The wrists and small joints of the hands are invariably involved in RA and so their 
evaluation is of considerable importance. Due to their relative shallow depth they are 
easily amenable to evaluation with ultrasound utilising higher frequencies that 
produce high resolution images. Potentially, musculoskeletal ultrasound may be a 
useful tool in the diagnosis and prognostication of early RA. It is easy to use, has low 
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running costs, is non-invasive, and interactive with the patient. The examination does 
not involve ionising radiation, is multiplanar and visualises structures in real time 
[88].  
Grey scale ultrasonography has been used for some time for the detection of joint 
and soft tissue inflammation. As with all ultrasound techniques, it utilises reflected 
pulses of high frequency sound waves to assess various structures. Different 
intensities of reflected sound waves, or echoes, are then represented in black, white 
and various shades of grey.  Grey scale ultrasound can demonstrate early erosions 
in RA which is an important prognostic parameter in patients with arthritis [89] with 
good interobserver agreement [90]. It may also be more sensitive than MRI in the 
detection of synovitis and tenosynovitis and can reproducibly delineate synovial 
thickening in small joints of the hands in patients with active RA. The analysis of 
such images however does not necessarily demonstrate a clear relationship with 
clinical assessments of disease activity [91]. This observation may reflect the fact 
that grey scale US identifies synovial thickening without differentiating actively 
inflamed or fibrous tissue, alternatively it may reflect the increased sensitivity of US 
in detecting joint inflammation when compared to clinical examination. This was 
illustrated in a study of 44 patients with early RA where clinical evaluation was 
compared with US assessment of a range of large and small joints. US detected 
signs of joint inflammation in 50.6% of joints with good levels of agreement between 
two readers, while clinical examination found only 32.1% [92]. 
More recently, additional US techniques, such as Doppler, have been introduced 
which provide haemodynamic information in real time. There are two main types of 
Doppler US used in musculoskeletal imaging, colour flow (CF) and power Doppler 
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(PD). Ultrasound images of flow, whether colour flow or power Doppler, are 
essentially obtained from measurements of movement. Reflected ultrasound echoes 
from stationary tissue are the same from pulse to pulse whereas echoes from 
moving objects (such as red blood cells) exhibit slight differences in the time for the 
signal to be returned to the receiver. These differences can be measured as a direct 
time difference, or as phase shift from which the ‘Doppler frequency’ is obtained. In 
colour Doppler, real-time presentation of flow information in colour is superimposed 
on the grey-scale image. Analysis is performed in the colour box, which is divided 
into cells. Each cell behaves like an independent Doppler gate with its own Doppler 
analysis. The mean frequency shift for each cell is computed and displayed as a 
colour. 
PD displays power or amplitude of the Doppler shift in each cell, instead of the mean 
frequency shift.  This is related to the volume of blood present and gives PD a 
theoretical advantage over colour Doppler with regard to sensitivity. Disregarding 
direction of flow (negative or positive frequency shift) and disregarding velocity (high 
or low frequency shift) the power (energy) of the many different frequency shifts 
inside a cell are added to form the power signal. In this way colour flow Doppler is 
better suited for evaluating high-velocity flow in large vessels (e.g. carotids), whereas 
PD is better suited for assessing low velocity flow in small vessels such as in the 
synovium [93]. 
PDUS enables detection of synovial hyperaemia in the inflamed RA joint, and has 
been found to provide a reliable and accurate method for visualising blood flow 
within the synovial tissue, with highly significant correlation to histologic findings of 
synovial vascularity [94]. Szkudlarek et al found PDUS to be a reliable method for 
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assessing joint inflammation. In 2001 they performed PDUS and dynamic MRI on the 
MCP joints of 15 patients with active RA and 12 controls. Using dynamic MRI as a 
reference, PDUS had a sensitivity of 88.8% and a specificity of 97.9%, whereas 
PDUS and clinical assessment of joint swelling were only weakly correlated [95]. 
Grey scale US has also been shown to identify ongoing synovial hypertrophy in 84% 
of a large cohort of patients defined as being in clinical remission by their treating 
physician. 60.4% of these patients had increased PDUS signal confirming active 
synovitis, again illustrating the superior sensitivity of US in the detection of synovial 
inflammation compared with clinical examination [96]. In this study, subclinical 
inflammation detected by grey scale and power Doppler ultrasound also predicted 
the progression of joint damage in patients with RA. The use of a microbubble based 
US contrast agent may further improve the detection of intra-articular vascularisation 
in the finger joints of patients with RA [97,98]. However, this finding is not consistent, 
and use of contrast agents increases cost, time and invasiveness of the examination, 
and also limits the number of joints that can be assessed per examination [99]. 
A consensus has defined an RA bone erosion on ultrasound examination as an intra-
articular discontinuity of the bone surface that is visible in 2 perpendicular planes. 
Sonography can enable detection of more erosions than radiography particularly in 
early RA, although the sensitivity is improved at more easily accessible joints such 
as the second and fifth MCP joints of the hand, where visualisation is possible from 
three aspects [100]. This was illustrated in a study by Wakefield et al who recorded 
erosion sites revealed by radiography and US, at the MCP joints of 100 patients with 
RA. MRI was also performed in a number of these patients to confirm the 
pathological specificity of sonographic erosions. In early disease US detected 6.5 
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fold more erosions than did radiography, in late disease the difference was 3.4 fold. 
A preponderance of erosions occurred at the second MCP joint, with 73% occurring 
on the radial or ulnar sides of the joint, 25% on the dorsal aspect and only 2% on the 
volar aspect. All US erosions not visible on radiography corresponded by site to MRI 
bone abnormalities, confirming its reliability [101]. A more recent study compared 
erosions detected at the MCP joints by MRI and US to those detected by computed 
tomography (CT). With CT as the standard reference method, high specificity of MRI 
and US in detecting bone erosions in RA MCP joints was demonstrated, indicating 
that radiographically invisible bone erosions detected by both imaging modalities are 
true erosive changes [100]. 
In addition to enhanced detection of synovial inflammation, PDUS also allows  
quantitative assessment of vascularity. A reduction in the PD signal has been 
observed following therapeutic intervention in a randomized, placebo-controlled 
study of anti-TNF therapy in early rheumatoid arthritis [102] as well as other small 
uncontrolled studies [103,104]. Thus ultrasonography may well be a feasible imaging 
modality for detection of treatment response in patients with RA, allowing accurate 
monitoring of disease activity in the clinical setting.  
Traditionally, musculoskeletal ultrasound has been performed with the use of 
equipment which deliver two-dimensional images. Standardising these images 
requires skill and training to acquire optimum information and reduce inter- and intra-
observer variability. Three-dimensional (3D) US generates volumetric images 
containing the entire PDUS signal within the acoustic window, representing the 
summation of a virtually infinite number of conventional two-dimensional (2D) images 
[105]. The process of acquisition in 3D US is automated, requiring only a few 
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seconds per small joint, and can be performed by a relatively unskilled operator. In 
comparison with 2D power Doppler, 3D mode potentially reveals more, very small 
blood vessels in connection with the whole blood vessel tree, and provides a new 
opportunity to study the architecture and alterations of synovial vasculature [106]. 
Thus 3D ultrasound promises to be a useful tool in the detection and monitoring of 
synovial inflammation whilst minimising margin of error. 
Hypothesis for this Study: 
• Power Doppler ultrasound can be used as a prognostic tool to predict the 
progression of erosive disease in early rheumatoid arthritis (in the absence 
of biologic therapy). 
 
As such, the objectives of the study analysis were as follows: 
 
• To determine whether results from an ultrasound scan can predict 
whether a patient has significant deterioration of RA after 12 months of 
treatment. 
 
• To determine whether the predictive value of ultrasound scan results can 
be improved using other variables such as ESR, CRP and demographic 
information. 
 
 
The primary outcome variables considered for the analysis were those reflecting 
progression of structural damage in the small joints of patients - namely change in 
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VdH Sharp score from baseline to twelve months, and change in ultrasound erosion 
score over the same period. 
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2 METHODOLOGY 
2.1. Patients 
In order to investigate the hypothesis, an observational, prospective study was 
designed; recruiting RA patients prospectively with 1987 ACR defined RA with 
symptom onset within the previous 3 years. Patients were over the age of 18 and 
seropositive for anti-CCP antibody and / or IgM Rheumatoid factor as measured by 
agglutination assay. Only seropositive patients were recruited as there was a limited 
time scale available over which the study was conducted and these patients tend to 
have more aggressive disease and thus develop structural joint damage earlier than 
patients who are seronegative for rheumatoid factor and / or anti-CCP antibody. 
Patients were allowed to continue or alter their RA medication as determined by their 
treating physician; however patients were excluded should they have current or past 
use of biologic drugs.  
The reasoning behind this decision was because the hypothesis investigated herein 
presupposes that the eradication of radiographic progression is achieveable through 
the eradication of synovial inflammation. However, recent analyses have shown a 
disconnect between clinical and radiographic outcomes where inhibition of 
radiographic progression was achieved even in patients with significant residual 
disease activity treated with TNF inhibitors [131]. This suggests an uncoupling 
between structural damage and inflammation in patients treated with these agents 
which does not exist with patients treated with conventional DMARDS. Interestingly, 
Aletaha and colleagues have demonstrated a similar dissociation between clinical 
and structural outcomes in patients treated with rituximab suggesting that the 
mechanism explaining this dissociation is not unique to anti-TNF drugs [132]. 
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The Anti-TNF-α Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) 
was the first study to suggest the notion of disconnect, or uncoupling, between 
damage and inflammation when they showed a reduction in total sharp score in RA 
patients treated with a combination of infliximab and methotrexate who showed no 
improvement in clinical signs of disease activity compared with patients on 
methotrexate and placebo [133]. Similar findings have been shown in early RA and 
with other anti-TNF agents [134]. 
At screening all patients underwent clinical and laboratory assessments, and once 
informed consent was obtained, were enrolled onto the study to undergo their 
baseline visit within 28 days of screening. Study visits took place at 0, 6 and 12 
months, each comprising clinical, laboratory and ultrasound assessment, with 
radiographs of the hands and feet also performed at 0 and 12 months. All study visits 
took place during the morning, and all patients were seen at the same time of day at 
each visit. 
The protocol was approved by the Hammersmith Research Ethics Committee. 
 
2.2. Clinical Assessment 
Clinical evaluation was performed for all patients by a Rheumatology research nurse, 
who was blinded to the US and radiographic findings and who was not involved in 
the treatment decisions. 
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At each visit, 28 joints including bilateral glenohumeral, elbow, wrist, 
metacarpophalangeal (MCP), proximal interphalangeal (PIP) of the hands, and knee 
joints were assessed for tenderness and swelling. Tender joint count and swollen 
joint count were recorded for each patient. A Visual Analogue Score (VAS) for the 
patient’s overall assessment of disease activity (range 0–100 mm), a global pain 
intensity VAS score, duration of early morning stiffness and a physician VAS for 
overall disease activity was recorded at each visit. Functional status was determined 
by the HAQ score and also Belza Fatigue score from the Belza fatigue 
questionnaire, and medications received were recorded at each visit. 
 
2.3. Radiographic evaluation 
Radiographs of the hands and feet of all patients were obtained at baseline and one 
year. Radiographs were scored in chronological order for both erosions and joint 
space narrowing, according to the modified Sharp/van der Heijde method by 
clinicians blinded to the identity, treatment, and clinical status of the patients. If RA 
subjects were prescribed a biological treatment: Etanercept, Adalumimab, Infliximab, 
Anakinra, Rituximab, and / or other biological drugs which may have come onto the 
market during the course of the study, these patients were excluded from further 
analyses. 
2.4. Laboratory Assessments 
At each study visit, all patients had CRP and ESR measured as well as blood taken 
for full blood count, liver function and renal function. 
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2.5. Power Doppler and Grey Scale Ultrasonography 
All subjects underwent grey scale and power Doppler 2D ultrasound assessment of 
all 10 MCP joints, which were scanned over the dorsal surface in the transverse and 
longitudinal planes.  
The same sonographer scanned the joints of each subject at all visits to ensure 
consistency. All images were anonymised and stored for subsequent analysis using 
a computerised image analysis system. Images were scored separately for synovial 
thickening and vascularity against an analogue scale from 0 – 4 where 0 was no 
hypertrophy or vascularity and 4 = severe hypertrophy or vascularity (1 = minimal, 2= 
mild and 3 = moderate). Synovial thickening was scored on grey scale images and 
vascularity on power Doppler images. 
Both hypertrophy and vascularity were also calculated by pixel count in a defined 
region of interest for each joint. Erosion number in each MCP joint was also 
determined on grey scale images with an erosion defined as an intra-articular 
discontinuity of the bone surface that is visible in 2 perpendicular planes. In addition 
all subjects underwent 3D ultrasound assessment of all 10 MCP joints and both 
wrists in PD mode with images stored for subsequent analysis using a computerised 
image analysis system.  
With a view to standardization of data acquisition, the hand was maintained in a 
position of rest by a splint. Scanning was performed in one room in which the 
temperatures were maintained at a constant level all year (≈20°C), with a delay of at 
least 10 minutes if patients arrived from the outside. Care was taken when scanning 
to avoid undue pressure with the probe in case this altered blood flow in the joint. 
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Summary List of Ultrasound Endpoints  
1. Sum of 10 MCP Joints 2D Semi-quantitative transverse synovial thickness 
scores (MCP 2D Trans STi). 
2. Sum of 10 MCP Joints 2D Semi-quantitative transverse synovial vascularity 
scores (MCP 2D Trans VASCi). 
3. Sum of 10 MCP Joints 2D Semi-quantitative longitudinal synovial thickness 
scores (MCP 2D Long STi). 
4. Sum of 10 MCP Joints 2D Semi-quantitative longitudinal synovial vascularity 
scores (MCP 2D Long VASCi). 
5. Sum of 10 MCP Joints 2D Semi-quantitative transverse synovial thickness 
area (MCP 2D Trans STA). 
6. Sum of 10 MCP Joints 2D Semi-quantitative transverse power Doppler area 
(MCP 2D Trans PDA). 
7. Sum of 10 MCP Joints 2D Quantitative longitudinal synovial thickness area 
(MCP 2D Long STA). 
8. Sum of 10 MCP Joints 2D Quantitative longitudinal power Doppler area (MCP 
2D Long PDA). 
9. Sum of 10 MCP Joints 3D Semi-quantitative synovial vascularity                    
(MCP 3D VASCi). 
10. Sum of 10 MCP Joints 3D Quantitative power Doppler volume            
 (MCP 3D PDV).      
11. Sum of both Wrist joints 3D Semi-quantitative synovial vascularity                    
(WRIST 3D VASCi). 
12. Sum of both Wrist joints 3D Quantitative power Doppler volume            
(WRIST 3D PDV).     
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All ultrasound scanning undertaken for the study in both 2D and 3D mode were 
performed by myself, as well as all analysis and interpretation of the images as 
described in the following section. 
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Table 2.1. STUDY SCHEDULE: 
 Screening 0 months 6 months 12 months 
Informed consent    *    
Medical History    *    
Physical  
Examination 
   *    
Rheumatological 
Examination 
     *     *    * 
Ultrasound 
Scan 
     *     *    * 
Blood for anti-CCP / 
RF 
   *    
Blood for FBC/LFT 
/U&Es /CRP/ESR 
   *     *     *    * 
Hands & Feet 
X-rays 
     *     * 
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2.6. METHOD OF ANALYSIS: Ultrasonography 
2.6.1. Two Dimensional Imaging: 
PDUS was graded in each MCP joint using a Synovitis Vascularity Scale (VASCi), 
an ordinal scale of 0 to 4 in both longitudinal and transverse planes, with 0 
representing the lack of PDUS signal and 4 being severe PDUS signal. This was 
graded against a library of representative images. Synovial thickness (STi) was also 
measured using grey scale ultrasound. Synovial thickness was graded in each MCP 
joint against a standardized image set (0-4).  All longitudinal 2D images were 
recorded in the longitudinal axis defined by the metacarpal head and proximal 
phalange so that the probe was bisecting the joint. All transverse images were 
recorded in the deepest part of the joint between the metacarpal head and base of 
the proximal phalange called the triangular structure. 
Settings:    
Grey scale    Power Doppler mode   
Frequency 14MHz   Frequency 7.5 MHz 
Gain 50    Gain 41 
Depth 2.0cm    Pulse Repetition Frequency 1.4kHz 
Frame Rate 24   Wall Filter 127Hz 
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Fig: 2.1. Normal 2D MCP joint: 
 
 
Schematic illustrates the measurements of an MCP joint performed on a dorsal 
longitudinal US scan obtained in a volunteer. a = maximum length of the dorsal 
metacarpal synovial recess, b =maximum thickness of the dorsal metacarpal 
synovial recess, c = maximum thickness of the synovium over the dorsal metacarpal 
headtubercle (*), d = maximum thickness of the metacarpal head cartilage, e = 
maximum height of the dorsal triangular structure, f = maximum depth of the 
metacarpal head depression, M = metacarpal head, P = phalangeal base. 
Boutry et al: Radiology:232:3:716-724 
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Grey scale synovial thickening: 
 
 
 
 
 
Minimal synovial thickening in 
study patient designated 1 on 
ordinal scale 
 
Transverse image  
 
Mild synovial thickening in study 
patient designated 2 on ordinal 
scale 
 
Longitudinal image 
 
Minimal synovial thickening in 
study patient designated 1 on 
ordinal scale 
 
Longitudinal image  
 
Phalangeal	  base	   	   	   	  
Metacarpal	  head	  	  	  
Joint	  space	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Mild synovial thickening in study 
patient designated 2 on ordinal 
scale 
 
Transverse image 
Transverse image 
Moderate synovial thickening in 
study patient designated 3 on 
ordinal scale 
 
Longitudinal image 
 
Moderate synovial thickening in 
study patient designated 3 on 
ordinal scale 
 
Transverse image 
 
Hypoechoic	  tissue	  indicative	  of	  synovial	  
hypertrophy	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Severe synovial thickening in 
study patient designated 4 on 
ordinal scale 
 
Longitudinal image  
 
Severe synovial thickening in 
study patient designated 4 on 
ordinal scale 
 
Transverse image 
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Examples of Power Doppler Signal in MCP joints: 
 
 
 
 
 
Mild PDUS signal designated 2 
on ordinal scale 
 
Transverse image 
 
Moderate PDUS signal 
designated 3 on ordinal scale 
 
Transverse image 
 
Moderate PDUS signal 
designated 3 on ordinal scale 
 
Longitudinal image 
 
Digital	  vessel	   	   	   PD	  signal	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2.6.2. Erosion detection: 
 
 
 
 
 
Severe PDUS signal designated 
4 on ordinal scale. 
 
Transverse image 
 
An erosion is 
defined as an intra-
articular 
discontinuity of the 
bone surface that is 
visible in 2 
perpendicular 
planes.  
 
Erosions are 
detected in grey 
scale mode and 
counted in each 
MCP joint. 
Erosion	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The power Doppler area (PDA) and synovial thickness area (STA) was also  
calculated as a count of the number of pixels with power Doppler signal or synovial 
thickening, both corrected and uncorrected by pixel intensity, within a defined region 
of interest in a standardized 2-dimensional image of the joint: 
 
 
 
Longitudinal PDUS image, 
analysis performed on 
frame number 5 selected 
from clip to reveal most 
power Doppler signal.  
Doppler pixel count = 2051 
Number of pixels of high 
intensity Doppler signal= 
257 
Longitudinal grey scale 
image, analysis 
performed for synovial 
thickening 
Area of interest = 
35773 pixels 
	  
72	  
	  
2.6.3. Three Dimensional Ultrasound Imaging: 
Original method of analysis: 
 
 
 
Image A: Transverse view  Image B: Longitudinal view 
Image C: Coronal view  Image D: Composite 3D view 
The relevant image is opened 
using the GE logiq works 
software and viewed as an FX 1 
Up in order to access the Raw 
DICOM data. 
This Raw DICOM image is 
exported to the Exchange File 
which is opened to convert the 
saved Raw DICOM image into a 
volume file.  
The GE 4D View Programme is 
started and the saved image 
opened as shown.  
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The margins of the 3D 
image are enlarged until it 
fills the whole 3D image. 
This is then accepted as the 
Region of Interest (ROI). 
Press “VOCAL II” and 
manually position the red-
dotted line in the centre of 
the MCP joint in Image C 
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The green arrows which will 
define the outer limits of the 
sphere are then manually 
positioned 
The contour of the sphere is 
defined by rotating it through 
the entire 360 degrees in 15 
degree steps whilst 
simultaneously altering the 
margins in order to include 
vessels of interest and exclude 
irrelevant vessels. This new 
contour will be used for the final 
VOCAL (Volume Calculation) 
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The contour is accepted 
and the image reviewed by 
first pressing “Render 
Mode”. This can be 
reviewed as a glass body 
image as shown on the left 
or a colour only image as 
shown below. The glass 
body image allows both 
synovial / digital vessels to 
be viewed in relation to the 
joint itself. The digital 
vessels can then be 
removed using the Magicut 
tool.	  The percentage of 
colour voxels to grey scale 
image is obtained by 
pressing” View” and then 
“Histogram”. The 
Vascularisation Flow Index 
(an average flow velocity of 
the coloured voxels) will be 
noted.	  
The Volume of coloured 
voxels in cm3 is calculated 
by pressing “View”, then 
“Threshold Volume”. The 
VI is divided by 100 and 
the product multiplied with 
the Volume (by Histogram)	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There are however problems with this method of analysis of 3D images. The contour 
of the sphere is fixed at four points (at 0, 90, 180 and 270 degrees) which causes 
some inflexibility in defining the correct margins of the joint. In addition the margin of 
the joint created manually to include vessels of interest and exclude irrelevant 
vessels, is defined by image C on the scan (bottom left hand image) which rotates in 
one axis. However by rotating image B (top right hand corner) it becomes obvious 
that the removal or addition of vessels in this one axis alone is not sufficient, allowing 
parts of digital vessels or artefactual PD signal to remain behind. This causes 
inaccuracy and inconsistency in the calculated volume of power Doppler within the 
joint space. 
 
 
Current method of 3D analysis: 
 
 
 
 
The	  relevant	  image is opened 
using the GE logiq works 
software and viewed as an FX 1 
Up in order to access the Raw 
DICOM data. 
This Raw DICOM image is 
exported to the Exchange File 
which is opened to convert the 
saved Raw DICOM image into a 
volume file.  
The GE 4D View Programme is 
started and the saved image 
opened as shown.	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The area of interest is 
defined by reducing the 
margins of the image with 
reference to transverse, 
longitudinal and coronal 
views.  Only the joint is 
included in order to limit 
background artefact. 
This region of interest is 
then accepted  by pressing 
“Accept ROI” 
The display is then 
changed to single display 
which brings up the single 
composite 3D image. The 
image is magnified and the 
intensity of the colour 
voxels increased to allow 
better visualisation of blood 
vessels / flow. (This does 
not affect the calculation of 
PD volume) 
Digital	  vessel	  
Visible	  PD	  signal	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Change the render mode to 
glass body to allow 
visualisation of blood 
vessels in relation to the 
joint space. However in this 
plane it is difficult to see if 
the visible PD signal, shown 
on the image, lies within the 
synovial space or outside 
the joint capsule. 
To localise the visible PD 
signal, the image is rotated 
anticlockwise through 90 
degrees and sliced through 
the visible PD signal by 
pressing Magicut “grey and 
colour” and drawing a line 
manually through the area 
to be viewed. 
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The sliced image is rotated 
in the X axis to bring the 
sliced plane into view. The 
transparency on the image is 
reduced to minimal to allow 
only the cut plane to be 
visualised. This allows 
accurate localisation of the 
PD signal, which is seen 
here within the joint space 
and can thus be assumed to 
be “true” synovial signal. The 
magicut is then undone so 
the whole image is restored 
after making note of the 
location of the signal.  
Here the image has 
been restored, and a 
magicut performed in 
grey scale only, in 
order to “lift the lid” on 
the joint. The colour 
voxels are not affected, 
thus the inside of the 
joint can be visualised 
in the coronal plane in 
relation to the blood 
vessels 
Digital	  vessels	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In the next step, the 
periphery of the image 
is cut away, leaving 
only the joint itself. 
The render mode is 
changed to colour, 
enabling visualisation 
of PD signal only. 
Metacarpal	  head	  
	  
	   	   	   	   	   	   	  	  	  	  	  Phalangeal	  base	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This method of 3D analysis while initially more cumbersome, does allow more 
accurate localization of true intra-articular PD signal. In addition artefactual PD signal 
is minimized by including only the joint space. It also yields more consistent results 
than the original method. 
 
 
 
 
 
 
The remaining digital vessels are cut 
away, leaving only the intra-articular 
PD signal.  
The percentage of colour voxels to 
grey scale image (VI or 
Vascularisation Index) is obtained by 
pressing “View” and then 
“Histogram”. The Vascularisation 
Flow Index (an average flow velocity 
of the coloured voxels) will be noted. 
The Volume of coloured voxels in 
cm3 is calculated by pressing “View”, 
then “Threshold Volume”. The VI is 
divided by 100 and the product 
multiplied with the “Volume” (by 
Histogram). This gives the volume of 
coloured voxels in cm3.  
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Wrist analysis: 
 
 
 
 
The	  relevant	  image is 
opened using the GE 
logiq works software and 
viewed as an FX 1 Up in 
order to access the Raw 
DICOM data. 
This Raw DICOM image 
is exported to the 
Exchange File which is 
opened to convert the 
saved Raw DICOM 
image into a volume file.  
The GE 4D View 
Programme is started 
and the saved image 
opened as shown.	   
The margins of the 
3D image are 
enlarged until it fills 
the whole 3D image. 
This is then 
accepted as the 
Region of Interest 
(ROI). 
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The display is then 
changed to single 
display which brings 
up the single 
composite 3D image. 
The image is 
magnified and the 
intensity of the colour 
voxels increased to 
allow better 
visualisation of blood 
vessels / flow. 
The blood vessels are 
cut away, leaving only 
the intra-articular PD 
signal.  The volume of 
PD signal is then 
calculated as 
previously 
documented. 
 
Intra-­‐articular	  PD	  signal	  within	  wrist	  
84	  
	  
2.7. METHOD OF ANALYSIS: Radiographic scoring 
All patients who completed the study underwent radiographs of hands and feet at 
their baseline and their final visit. For the purpose of this study, the Van der Heijde 
modification of Sharp score was utilised to evaluate radiographic disease 
progression. The images were evaluated by two raters – myself and Dr Benjamin 
Fisher, reading the films in paired chronological order. 
Scoring of hands: 
Scoring is divided into scores given for erosions (range 0 – 5) and separately for joint 
space narrowing (JSN) which also includes scores for joint subluxation or luxation 
(range 0-4).  
Erosions are scored in 16 joint areas per hand, allowing for a maximum score of 80 
in each hand. A score of 1 is given for a discrete erosion, and 2 or 3 if they are 
larger, depending on the surface area involved. A score of 4 is given if the erosion is 
very large and extends over the middle of the bone and a score of 5 equates to 
complete collapse of the joint or if the full surface of the joint is affected. 
Joint space narrowing is scored in 15 selected joints in the hand and wrist. The score 
ranges from 0 – 4 in each joint with 0 equating to a normal joint space, 1 given to 
joints where the space is focally narrowed, scores of 2 and 3 given to joints where 
there is reduction of less than 50% of joint space and greater than 50% of joint space 
narrowed respectively and 4 equates to ankylosis of the joint. The maximum score is 
thus 60 for each hand. 
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Scoring of feet: 
In the feet, erosions are evaluated on each side of the 10 metatarsophalangeal 
(MTP) joints and also the 2 interphalangeal joints of the great toes, with erosions 
being defined in the same way as in the hands (see above). The maximum erosion 
score for each foot is thus 60. 
Criteria for scoring of JSN are identical to those of the hands and thus the maximum 
score for JSN in each foot is 24. 
Summing of scores: 
Maximal total erosion score of the hands is thus 160. Maximal total erosion score of 
the feet is 120. Maximal total erosion score (hands and feet) is 280.  
 Maximal total narrowing/(sub)luxation score in the hands is 120. Maximal total 
narrowing/(sub)luxation score in the feet is 48. Maximal total narrowing/(sub)luxation 
score (hands and feet) is 168. 
 Maximal total Sharp/van der Heijde score per patient is thus 448. 
For the purposes of this study, scoring sheets were used to score radiographs of the 
hands and feet where the location of each erosion and area of JSN was marked with 
the score given for each. 
Fig 2.2.  Van der Heijde modification of Sharp Score: Joints and sites scored for JSN (left 
panel), joints and surfaces of the joints scored for erosions (middle panel), examples of 
scoring erosions (right panel). The small numbers indicate how an erosion is scored with the 
total erosion score given in the box. 
From Van der Heijde D.,Balliere’s Clinical Rheumatology. 1996;10;435-453 
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2.8. STATISTICAL ANALYSIS 
For details of methodology of statistical analysis please see sections 3.2. and 3.3. in 
the results chapter (pages 92 and 98). 
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3 RESULTS 
3.1 Descriptive Statistics 
Table 3.1. Summary of primary outcome variables ( F = female and M = male) 
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3.1.1. Patient characteristics 
100 patients were recruited to the study, of these 6 were transferred to biologic 
treatment and 9 were lost to follow up. 85 patients completed the study and the 
results will concentrate on these completers. Of these patients 64 were female and 
21 male. The ages of the patients ranged from 23 to 79 with a mean of 50. 
3.1.2. Clinical characteristics 
The median duration of RA for these patients was 12 months at enrolment (range 3-
35 months). 71 of 85 (83%) patients were taking methotrexate at baseline with an 
average dose of 12.7mg/week. 6 patients were taking sulphasalazine with a mean 
dose of 2g/day, 3 of these patients were co-prescribed methotrexate. 23 patients 
were taking hydroxychloroquine with a mean dose of 295mg/day, 21 of these 
patients were also taking methotrexate and 1 patient sulphasalazine. Just one 
patient was taking leflunomide at 20mg/day. 21 patients had been treated with oral 
prednisolone at the time of their baseline visit, at a mean dose of 8 mg/day (range 
2.5-20mg/day). 
At baseline mean CRP level was 10.8 and ESR was 22.9 with a DAS 28 score of 
4.07. At twelve months average DAS 28 had fallen to 3.66, CRP fell to 3.6 and ESR 
to an average of 18.5. At baseline, average HAQ score was 0.86 with Belza fatigue 
score of 20.07. At twelve months, HAQ score had fallen to 0.72 and Belza fatigue 
score to 18.2.  
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Table 3.2. Summary of other independent variables at baseline (where EMS is 
Early morning stiffness). 
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3.1.3.Ultrasound Results 
In the entire patient cohort, there were a total of 76 erosions seen in 35 patients on 
US at the MCP joints (range 0 – 6). By 12 months this rose to 204 MCP joint 
ultrasound erosions seen in 60 patients (range 0 – 11).  
Table 3.3. Ultrasound erosions by location 
MCP 
Joint 
L1 L2 L3 L4 L5 R1 R2 R3 R4 R5 
Baseline 12 14 2 0 6 8 24 4 0 6 
12 
months 
23 32 11 0 19 26 58 9 1 25 
 
Mean baseline total MCP 3D power Doppler volume was 42.89 mm3 with a range 
from 0.8mm3  - 722.1mm3. At twelve months, mean total MCP 3D power Doppler 
volume had decreased to 24.49 mm3 with a range from 0.3 mm3 - 360.3 mm3. 
At the wrists, mean baseline total 3D power Doppler volume was 412.78 mm3 with a 
range of 31.3 mm3 – 2020.6 mm3. At twelve months mean wrist volume was 246.95 
mm3 with a range from 18.8 mm3 - 1467 mm3. 
2D ultrasound scores followed the same overall pattern with transverse and 
longitudinal scores of vascularity on both quantitative and semi-quantitative scales 
falling over the 12 month period. Generally longitudinal scores of vascularity scored 
higher than transverse scores in those patients with intra-articular PD signal present. 
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Conversely, transverse scores of synovial thickness were consistently scored higher 
than longitudinal scores in those patients with the presence of intra-articular synovial 
hypertrophy, although these also fell over the twelve month period. 
3.1.4. Radiographic results 
In the entire patient cohort, there were a total of 38 MCP joint radiographic erosions 
at baseline out of a total of 103 in the hands and 278 in hands and feet. At twelve 
months, this rose to 57 in the MCPJs out of a total of 176 in the hands and 430 in 
hands and feet.  
 
3.2. Raw data analysis 
The correlation between baseline parameters and change in both ultrasound erosion 
score and VdH Sharp score at 12 months (i.e: progression of structural damage to 
the small joints) was analysed from the raw data using the Spearman rank 
correlation coefficient as this was a non-normally distributed population: 
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Table 3.4 Correlation of progression of erosions on ultrasound with baseline 
parameters: 
 
 
Parameter  MCP 3D PD 
score 
(qualitative)  
Wrist 3D 
PD 
volume 
(mm3 )  
MCP 2D 
longitudinal 
PD area 
(quantitative)  
MCP 2D 
transverse 
PD area 
(quantitative)  
CRP  DAS 
28  
Spearman 
Rank 
Correlation 
coefficient 
0.58  0.43  0.43  0.50  0.39  0.34  
95% 
confidence 
interval  
0.42 to 0.71  0.23 to 
0.59  
0.24 to 0.60  0.32 to 0.65  0.18 to 
0.56  
0.13 to 
0.52  
P value < 0.0001 < 0.0001  < 0.0001  < 0.0001  0.0003  0.0015  
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Fig. 3.1. Correlation of progression of erosions on ultrasound with baseline 
MCP 3D power Doppler volume) 
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Table 3.5 Correlation of progression of VdH score with baseline parameters: 
 
 
Parameter  MCP 3D PD 
volume (mm3 )  
MCP 2D 
longitudinal PD 
area 
(quantitative)  
MCP 2D 
longitudinal PD 
score 
(qualitative) 
MCP 2D 
transverse PD 
score (qualitative)  
Spearman Rank 
Correlation 
coefficient 
0.48  0.53  0.48  0.46  
95% confidence 
interval  
0.29 to 0.63  0.35 to 0.67  0.29 to 0.64  0.27 to 0.62  
P value < 0.0001 < 0.0001  < 0.0001  < 0.0001  
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Fig. 3.2 and 3.3. Correlations between change in VdH Sharp score at 12 
months and vascular markers at baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 20 40 60
0
500
1000
1500
2000
2500
Spearman r
95% confidence interval
P value (two-tailed)
0.5675
0.3965 to 0.7004
< 0.0001
CHANGE IN VdH SCORE
B
as
el
in
e 
to
ta
l w
ris
t 3
D
 P
D
V 
(m
m
3 )
0 20 40 60
0
200000
400000
600000
Spearman r
95% confidence interval
P value (two-tailed)
0.5336
0.3547 to 0.6747
< 0.0001
CHANGE IN VdH SCORE
B
as
el
in
e 
M
C
P 
Tr
an
sv
er
se
Po
w
er
 d
op
pl
er
 a
re
a
98	  
	  
Fig. 3.4 and 3.5 Correlations between change in VdH Sharp score at 12 months 
and baseline CRP and disease activity score 
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Thus the correlations seen with the raw data indicated that although structural joint 
damage was possibly related to baseline inflammatory response and disease activity 
(as seen by the DAS 28); there was a stronger relationship between vascular 
synovial inflammation and structural joint damage as seen with two modalities - both 
ultrasound and x-ray. This would seem to implicate vascular tissue in the erosive 
phase of disease.  
The question then arose whether further analyses would yield results which had 
utility in patient management – i.e:  could a method be derived which would enable 
us to predict which patients would be at risk of severe structural progression and 
thus benefit from earlier intervention with biologic therapy? 
 
3.3. Statistical methodology 
Data was obtained for 85 patients for a total of 25 variables. These variables were 
categorised into five categories: outcome variables (2 variables), ultrasound scans 
(12), physiological risk factors for RA (6), demographic variables (2) and 
timing/baseline variables (3). A full list of variables collected in this study is shown in 
the table overleaf.  
For radiographic progression, we defined severe deterioration as a change in VdH 
Sharp score of 4 or more since this would equate with complete ankylosis or luxation 
of a joint. For ultrasound progression, we defined a change in ultrasound erosion 
score of 2 or more as denoting severe deterioration, as only MCPJs were scored for 
ultrasound erosions. 
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Table 3.6: Variables included in the analysis 
 
Outcomes US Scans Physiological Demographic Timing/baseline 
Change in VdH 
score 0-12mths 
(sqrt) 
Wrist 3D VASCi BMI (kg/m²) (log) Age (years) Time between x-
rays (weeks) 
Change in erosions 
0-12mths (sqrt) 
MCP 2D-
Transverse STi 
Erythrocyte 
Sedimentation Rate 
(log) 
Gender VdH score at 
baseline (sqrt) 
 MCP 2D-
Longitudinal STi 
C Reactive Protein 
(log) 
 Erosions at baseline 
(sqrt) 
 MCP 3D PDV (log) Anti-CCP titre (log)   
 Wrist 3D PDV (log) Duration of EMS 
(sqrt) 
  
 MCP 2D-
Transverse STA 
(log) 
Rheumatoid factor 
titre (sqrt) 
  
 MCP 2D-
Longitudinal STA 
(log) 
   
 MCP 2D-
Transverse VASCi 
(sqrt) 
   
 MCP 2D-
Longitudinal VASCi 
(sqrt) 
   
 MCP 3D VASCi 
(sqrt) 
   
 MCP 2D-
Transverse PDA 
(sqrt) 
   
 MCP 2D-
Longitudinal PDA 
(sqrt) 
   
Note: (log) denotes logarithmic transformation. (sqrt) denotes square root transformation. 
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Variables whose values were clustered predominantly about low values with a few 
extremely high values (i.e. right-skewed data) were transformed so that extreme 
values did not exert undue influence on the regression analyses. The logarithmic 
(log) transformation was preferred as the standard transformation. For variables with 
many zero values, a square root (sq root) transformation was used instead to avoid 
loss of data. 
 
For each of the two outcome variables, the analysis was conducted in three parts. 
Firstly, the crude bivariate relationship between the outcome variable and each 
ultrasound scan variable was evaluated using linear regression. The 3D-ultrasound 
variable with the best correlation with the outcome variable was selected to be 
carried forward to the second part (compared using R2). Additionally, a 2D semi-
quantitative vascularity score was selected based on the strongest correlation with 
the outcome variable for inclusion in the second part of the analysis.  
 
Secondly, an exploratory multivariate analysis was conducted using the two 
ultrasound variables selected from part one and each of the other variables 
(physiological, demographic and timing/baseline) singly in turn. (Note: the baseline 
score for the other outcome variable was excluded from this analysis). Variables 
were selected on the basis of improving the fit of the model over and above the 
“baseline” model (where no non-ultrasound explanatory variables were included), 
and the p-value of the new variable. The “Adjusted R2” value, which includes a 
penalty to compensate for the inclusion of extra explanatory variables, was used for 
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this purpose. It is derived using the formula Adjusted R2 = 1 - (1 - R2)[(N - 1) /( N - k 
– 1)], where N is the number of observations (in this case 85) and k is the number of 
predictor variables. 
 
Finally, a plausible multivariate model was arrived at by starting with a linear 
regression model including all variables carried forward from part 2 and eliminating 
variables one-by-one based on the highest p-value. In some cases, if the p-values 
were similar, the ultrasound variable was preferred to be absolutely sure of its non-
significance before excluding it. A “best” model was arrived at through this iterative 
process using the Adjusted R2 score as a diagnostic criterion. 
 
The validity and prognostic utility of each of the final models (one for each outcome 
variable) was assessed by evaluating the model's sensitivity and specificity in 
predicting deterioration in the outcome variable. For this purpose, the outcome 
variables were recoded as binary variables denoting “severe” deterioration (yes or 
no). For radiographic progression, we defined severe deterioration as a change in 
VdH Sharp score of 4 or more since this would equate with complete ankylosis or 
luxation of a joint. For ultrasound progression, we defined a change in ultrasound 
erosion score of 2 or more as denoting severe deterioration, as only MCPs were 
scored for erosions on ultrasound. 
All analysis was conducted using Stata 11 for Windows 
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3.3.1. Radiographic Progression (VdH score) 
The bivariate analysis of the crude association between change in VdH score and 
each ultrasound result are detailed in Table 3.6. (second column). Of these, MCPJ 
3D power Doppler volume (R2=0.34) and 2D longitudinal vascularity score (R2=0.33) 
were the 3D and 2D scores most strongly associated with change in VdH score. 
Figures 3.6 and 3.7 illustrate these bivariate relationships as scatterplots. 
 
3.3.2. Ultrasound progression 
On bivariate analysis, MCP joint power Doppler volume(log) was again the most 
useful 3D ultrasound variable for predicting change in ultrasound erosion score 
amounting to severe deterioration, whereas MCPJ 2D transverse vascularity score 
(sq root) was more useful than longitudinal score in this analysis. The correlations 
between these baseline measures and change in ultrasound erosion score >2 were 
stronger than for VdH score (R2 equal to 0.38 and 0.32 respectively). 
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Table 3.7: Results of bivariate analysis: correlation between 
radiographic/ultrasound progression and ultrasound variables measured at 
baseline visit 
Ultrasound scan R2 
(radiographic 
progression) 
R2 (ultrasound 
progression) 
(outcome variable:) Change in VdH 
sharp score 
Change in 
ultrasound erosion 
score 
Wrist 3D VASCi 0.212 0.085 
MCPJ 2D-Transverse STi 0.196 0.299 
MCPJ 2D-Longitudinal STi 0.199 0.319 
MCPJ 3D PDV* 0.338 0.381 
Wrist 3D PDV* 0.338 0.189 
MCPJ 2D-Transverse STA* 0.199 0.249 
MCPJ 2D-Longitudinal STA* 0.220 0.232 
MCPJ 2D-Transverse VASCi† 0.304 0.318 
MCPJ 2D-Longitudinal VASCi† 0.326 0.276 
MCPJ 3D VASCi† 0.293 0.378 
P<0.0005 for all correlations, except for ultrasound progression vs. Wrist 3D VASCi 
(p=0.007) 
* Log transformed 
† Square root transformed 
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Fig 3.6.. Scatterplot of change in VdH score against 3D MCPJ Power Doppler 
Volume 
 
Fig 3.7: Scatterplot of change in ultrasound erosions score against 3D Power 
Doppler Volume at MCPJs 
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Table 3.8: Exploratory multivariate analysis: linear regression of RA 
progression against two ultrasound variables and one other explanatory 
variable. 
 Change in VdH 
score† 
 Change in US erosions 
score† 
Ultrasound scan variables: 3D power doppler 
volume, 
2D-long. vascularity 
 3D power doppler 
volume, 
2D-trans. Vascularity 
Additional variable 
N Adj. 
R² 
P-value 
for new 
variable 
 N Adj. R² P-value for 
new 
variable 
None (baseline model) 84 0.348 NA  85 0.378 NA 
Age (years) 84 0.356 0.159  85 0.513 0.000 
Sex 84 0.367 0.065  85 0.428 0.005 
Time between x-rays (weeks) 82 0.337 0.571  82 0.374 0.945 
BMI (kg/m²)* 81 0.367 0.321  82 0.384 0.211 
Erythrocyte Sedimentation 
Rate* 
83 0.373 0.030  84 0.387 0.239 
C Reactive Protein* 84 0.396 0.008  85 0.420 0.010 
Anti-CCP titre* 80 0.327 0.412  81 0.368 0.555 
Duration of EMS† 84 0.356 0.153  85 0.370 0.892 
Rheumatoid factor titre† 84 0.342 0.642  85 0.382 0.204 
VdH score at baseline† 84 0.436 0.000  NA NA NA 
Erosions score at baseline† N
A 
NA NA  85 0.446 0.001 
 
 
107	  
	  
The results from the exploratory multivariate analysis are presented in Table 3.8 
(central set of columns). Three baseline variables yielded improved adjusted R2 
results with p<0.05: baseline VdH score, CRP, and ESR. Gender also yielded an 
improved adjusted R2 with p=0.065; as the objectives of this study were exploratory it 
was decided to include gender in the next part of the analysis, in addition to the other 
three variables (as well as the two ultrasound scans). 
Table 3.9 summarises the full multivariate analysis, which began with a linear 
regression including all six explanatory variables, eliminating one variable at a time 
during each iteration. After iteration 1, CRP was eliminated rather than 2D-
longitudinal vascularity score in order to fully explore the potential for a 2D 
vascularity score to contribute to the final model. However, there was still no 
evidence of any predictive contribution to the model of 2D-longitudinal vascularity 
score and it was eliminated after iteration 2. 
Models 3 and 4 appear to be of similar predictive value. Where gender is included as 
an explanatory variable (Model 3), its contribution does not reach the usual bounds 
of statistical significance (p=0.106), but excluding it reduces model fit, both in terms 
of unadjusted and adjusted R2. We now have a regression equation which estimates 
predicted change in VdH / erosion score using 3D PPDV, VdH score at baseline, 
ESR and sex. Using this regression equation we can attempt to predict which 
patients would have experienced severe degradationand compare these predictions 
to the actual change in scores to calculate the sensitivity and specificity of the test 
(Table 3.10). 
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Table 3.9: Multivariate analysis of RA progression against ultrasound and 
other variables carried forward from exploratory analyses. 
 
a. Radiographic progression (change in VdH score†). 
 P-value of independent variables  Model fit  
Mod
el # 
3D 
PDV
* 
2D-
Long. 
VASCi
† 
VdH 
score 
at 
baselin
e† 
C 
Reacti
ve 
Protei
n* 
Erythroc
yte 
Sedimen
tation 
Rate* Sex  R2 
Adj. 
R2 
Variable 
eliminated 
1 0.01
3 
0.505 0.003 0.380 0.107 0.17
9 
 0.50
7 
0.46
8 
CRP 
2 0.01
3 
0.432 0.001 .    0.014 0.09
4 
 0.50
2 
0.47
0 
2D-long. 
VASCi 
3 0.00
0 
.    0.001 .    0.009 0.10
6 
 0.49
8 
0.47
2 
Sex 
4 0.00
0 
.    0.000 .    0.016 .     0.48
1 
0.46
1 
(Process 
ended) 
 
b. Ultrasound progression (change in erosions score†). 
 P-value of independent variables  Model fit  
Model 
# 
3D 
PDV
* 
2D-
Trans. 
VASCi† Age 
Erosi
ons at 
baseli
ne Sex 
C 
Reacti
ve 
Protei
n*  R2 
Adj. 
R2 
Variable 
eliminated 
1 0.00
0 
0.548 0.00
0 
0.249 0.040 0.178  0.58
8 
0.55
7 
2D-trans. 
VASCi 
2 0.00
0 
.    0.00
0 
0.140 0.045 0.184  0.58
6 
0.56
0 
CRP 
3 0.00
0 
.    0.00
0 
0.051 0.027 .     0.57
7 
0.55
6 
Erosions at 
baseline 
4 0.00
0 
.    0.00
0 
.    0.020 .     0.55
6 
0.54
0 
(Process 
ended) 
Several equations were then modelled  using these 4 variables with the 2 ultrasound 
vascularity scores which estimated predicted change in VdH score. The equation 
which was the simplest was then tested as being the most statistically sound: 
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Table 3.10: Model equations, sensitivity and specificity of selected “final” 
models 
Model 
# 
Equation Sensitivity (%) Specificity (%) 
Radiographic progression (change in VdH score) 
3 √(change in VdH 
score) 
 
= -1.61  
+ 
0.433*log(power 
Doppler volume) 
+ 
0.220*√(baseline 
VdH score) 
+ 0.442*log(ESR) 
+ 0.503*(sex) 
63.2 
 
[95% CI: 47.1–
79.2] 
80.9 
 
[95% CI: 69.2–92.5] 
4 √(change in VdH 
score) 
= -0.892 
+ 
0.419*log(power 
Doppler volume) 
+ 
0.236*√(baseline 
VdH score) 
+ 0.402*log(ESR) 
67.6 
 
[95% CI: 51.7–
83.4] 
78.7 
 
[95% CI: 66.6–90.9] 
Ultrasound progression (change in ultrasound erosions score) 
3 √(change in 
erosions score) 
= -1.09  
+ 
0.289*log(power 
Doppler volume) 
+ 0.0180*(age)  
+ 
0.173*√(baseline 
erosion score)  
+ 0.314*(sex) 
54.2 
 
[95% CI: 32.7–
75.7] 
96.7 
 
[95% CI: 92.1–
100.0‡] 
Note: Power Doppler volume measured in mm3. Gender coded as 1=female; 
2=male. ‡ Estimated by formula as above 100%; rounded down to 100%. 
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For both radiographic and ultrasound progression, the low sensitivity and high 
specificity indicate that the utility of the test is in correctly identifying patients whose 
RA is likely to progress and who are candidates for more aggressive treatment, in 
the event of a positive test. A negative result, however, does not rule out the 
possibility of future RA progression.  
 
3.4 Reliability Analysis 
3.4.1. 2D reliability 
The method used was the Intra-class correlation co-efficient (ICC). This measures 
the correlation between different observations within some kind of pre-determined 
class. In our case, this "class" was in fact our individual subjects. For 2D measures, 
the US images for 10 patients chosen at random, were re-scored blindly at the end 
of the study by the original scanner for all three study visits. This then generated 
thirty classes with which we could test the inter-observer reliability by using ICC. 
The advantages of this method are that it's fairly simple to compute and interpret (the 
ICC is a number between 0 and 1 where 1 means complete agreement and 0 means 
complete disagreement) and measures absolute agreement of specific scores rather 
than relative agreement (e.g. this subject was better than that subject etc.). 
Graphs of variability for each of the 2D parameters were generated including 
captions stating the ICC and another measure, the group-mean reliability. Whereas 
ICC measures the reliability of one individual observer’s measurement, the group-
mean reliability measures the reliability of the measurement obtained if two 
observer’s scores were measured and the mean taken: 
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Figure 3.8. Intra-class correlation for 2D ultrasound scores  
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3.4.2 3D Reliability 
For 3D images, 10 patients were again chosen at random and their images for each 
of three study visits were re scored blindly by the original scanner for power Doppler 
volume. A second observer, Dr Pamela Mangat, also scored the same images 
independently using the method described earlier, after two hours training: 
 
Figure 3.9. Intra-class correlation for 3D power Doppler volume: 
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Generally results for both 2D and 3D reliability were excellent in all parameters 
measured. 
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3. CONCLUDING DISCUSSION 
4.1. Discussion 
The paradigm for the treatment of RA has evolved in the last few years such that 
accepted practice now involves early, aggressive intervention with drugs proven to 
ameliorate progression of disease and thus maintain functionality. However, the 
severity of disease varies between patients, both in the extent and pattern of joint 
involvement and also the rate of progression of erosions.  The disease course of 
persons who meet criteria for classification of RA may vary greatly from self-limiting 
to progressive erosive disabling forms. Currently there is no accurate nor reliable 
method by which we can predict the course of RA on an individual patient basis, and 
thus use this information to tailor treatment for individual patients, both in order to 
most effectively treat patients with aggressive RA but also to avoid unnecessary 
interventions in patients who have mild or self-limiting disease. 
 
Angiogenesis is a prominent feature of rheumatoid synovitis and essential to 
perpetuation of joint disease by delivery of cells and nutrients to the augmented 
inflammatory cell mass in involved joints. Serum VEGF levels at presentation with 
early RA has been shown to correlate highly significantly with development of 
radiographic damage over the subsequent year and RA patients with persistent 
disease activity despite conventional therapy have also been shown to have 
relatively high serum VEGF concentrations at first [21].  Power Doppler ultrasound 
scores from a selected joint set in patients with RA correlate significantly with serum 
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VEGF levels [107] and the vascular signal correlates also with histopathological 
quantification of synovial tissue vascular density [94]. 
Pilot data from studies at the Kennedy Institute of Rheumatology in a small cohort of 
patients with early RA using quantitative vascular imaging with PD ultrasound in a 
discrete joint set has demonstrated the capability of this technology to detect early 
response to anti-TNF therapy with greater sensitivity than traditionally used 
composite clinical scores of disease activity.  Furthermore, in this data based on a 
group of 12 patients with active RA despite methotrexate therapy, there was a 
significant correlation between baseline PD area and radiological deterioration as 
measured by progression in total van der Heidje Sharp score over one year (r= 0.78; 
p=0.005) [19]. 
This pilot data strongly supported the potential of vascular imaging as a prognostic 
biomarker and sensitive biomarker of response to therapy and gave rise to the 
hypothesis investigated herein. 
 
Both grey scale and power Doppler ultrasound have been found to have better 
sensitivity than clinical examination in the detection of inflammatory joint disease [95] 
with good construct validity [108]. In a study of 107 patients with RA judged to be in 
clinical remission by their rheumatologist, irrespective of which clinical criteria were 
applied to determine remission, the majority of patients continued to have evidence 
of active inflammation, as shown by findings on the imaging assessments. Even in 
asymptomatic patients with clinically normal joints, US showed that 73% had grey 
scale synovial hypertrophy and 43% had increased power Doppler signal [96]. 
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Importantly, in this cohort, 19% of the patients displayed deterioration in radiographic 
joint damage over the study period. Scores on musculoskeletal US synovial 
hypertrophy, power Doppler, and MRI synovitis assessments in individual joints at 
baseline were significantly associated with progressive radiographic damage with12 
times higher odds of deterioration in joints with increased PD signal [110]. 
Traditionally in both clinical trials and clinical practice, diagnosis and monitoring of 
disease in patients has relied on the use of conventional radiography, despite its 
many shortcomings as outlined previously. With the more contemporary emphasis 
on early treatment intervention and tight control of disease activity in RA, routine 
clinical practice has turned increasingly to more sensitive methods of detecting 
structural damage within RA joints, such as ultrasonography and MRI. 
Ultrasonography has been found to be a more sensitive and specific method of 
detecting joint erosions than conventional radiography, and in some studies is 
superior to MRI in this respect. A 2006 study in which the hand joints of 40 RA 
patients and 20 control persons were assessed with ultrasonography, clinical 
examination, radiography and MRI found 10 erosions in control patients on MRI and 
none on ultrasound. Small erosions were not always detected on MRI with poorer 
sensitivity seen at the PIP joints, even with extensive ultrasonographic changes. In 
addition ultrasonography detected synovitis more often in patients with early RA than 
did MRI, with the opposite being true in control patients in whom MRI revealed 
synovitis more frequently [110]. This finding is not universal however, with other 
studies demonstrating MRI as having greater accuracy in detecting both erosive 
change and synovitis [100]. Ultimately MRI and ultrasonography performance 
differences are probably caused by technical aspects such as accessibility for 
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ultrasonographic examination, with several studies showing that more erosions are 
detected in those joints with good accessibility by this modality (such as second and 
fifth MCPJ) than in joints only accessible in two planes (third and fourth MCPJ) 
[101,111]. This finding was shown to be true in our study, with the highest number of 
joint erosions on ultrasound found at the 1st, 2nd and 5th MCP joints both at baseline 
and at 12 months. Only 1 erosion was detected at the 4th MCP joint at 12 month 
follow up and thus the number of erosions detected by ultrasound in the study may 
well be an under representation of the true figure although this would be the case for 
numbers detected at both baseline and follow up. The resolution of ultrasonographic 
assessment, or thickness of the MRI slices (i.e: 3mm versus 1mm) could also 
influence the performance of the imaging modalities. Despite the arguably greater 
sensitivity and / or specificity of MRI, ultrasound is far easier to use, with less cost 
involved, is interactive with the patient and provides answers in real time. It can also 
be used in an outpatient clinic setting at the time of patient first presentation 
preventing delays in diagnosis and instigation of treatment. 
 
While results of imaging on ultrasound are user dependent, good inter- and intra-
observer reliability have been found consistently in the detection and grading of both 
synovitis and erosions, often with only a short period of training [90,112,113,114,115] 
and with better inter-observer reliability found particularly at the wrist, hand and knee 
rather than other joints scanned [113]. In part this reliability is probably secondary to 
the standardisation of scanning methods and OMERACT (Outcome Measures in 
Rheumatoid Arthritis Clinical Trials)	  definitions of both synovitis and erosions which 
we used in this study [125, 127]. In addition D’agostino et al developed a learning 
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curve for ultrasonographers with little or no experience in the assessment of 
synovitis in the MCP, PIP and MTP joints that shows that at least 70 examinations 
were necessary to develop US competence in assessing synovitis in the small joints 
of RA patients [116].  In our study, the scanner had experience of over 200 small 
joint scans prior to study initiation with excellent results for intra-observer reliability. 
 It is also important that US operators are aware of the technical limitations of 
ultrasound imaging as discussed above and that there are many variables that might 
influence an US image. These include factors pertaining to the machine (type of 
machine and transducer and control settings) and those that are not machine related 
(ambient temperature, transducer pressure and patient positioning) [128]. Doppler 
US signal appears particularly sensitive to all these factors and is easily reduced or 
obliterated by overextension or flexion of the joint, thus tightening the joint capsule 
and collateral ligaments resulting in compression of the vasculature. Additionally, 
compression may result from raised intracapsular pressure following certain joints 
positions especially if there is a synovial or fluid collection [129,130]. In our study the 
use of a constant ambient temperature and dedicated splint to maintain the hand 
being scanned in a position of neutrality would have reduced the effect of these 
variables on the US image obtained. 
 
Previous studies have also highlighted the predictive value of ultrasonography, Filer 
et al found that ultrasound demonstrated subclinical joint involvement particularly at 
the wrist, MTP and MCP joints of patients with very early synovitis, had value in 
predicting which of these patients developed RA [117]. Doppler studies of the wrists 
and / or small joints of the hands have also been found to have use as a marker of 
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response to treatment. Colour flow at baseline, measured as a fraction of the 
synovial tissue, was found to be the only outcome measure from a variety of other 
disease markers including DAS 28, which could predict which patients would stay on 
anti-TNF-α therapy for at least one year [119]. Improvement in power Doppler scores 
from baseline to two weeks was also found to be the best predictor of favourable 
tocilizumab treatment outcome after 24 weeks [119]. In addition, PD positive 
synovitis is a good predictor of unstable remission and has been found to be the 
main predictor of disease relapse in patients with clinical remission or low disease 
activity states [120]. An important finding is the high negative predictive value of the 
PD assessment, with a negative PD signal associated with stable remission in over 
90% of cases in one study, supporting a concept that a more complete remission 
might be defined by a negative PD signal [121]. 
 
The results described in this thesis indicate that all clinical parameters measured 
improved over a twelve month period. Despite this a significant proportion of patients 
developed new or progressive erosive lesions on both radiographs and ultrasound 
within this timeframe, with a third of patients experiencing severe deterioration on 
ultrasound and 44% on radiograph. Erosive progression has also been found to be 
significantly correlated with vascularity of the MCP joints at baseline, particularly as 
seen on 3D imaging, both evaluated semi-quantitatively and quantitatively. Synovial 
thickness at baseline was much more weakly correlated with structural damage 
which is consistent with previous findings of power Doppler signal as a more reliable 
indicator of disease activity [120,121]. 
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Interestingly, there was a weaker correlation seen with baseline 2D PDUS scores 
than 3D PDUS scores. This is interesting, since it may be postulated that 3D imaging 
of vascularity within the small joints is more accurate at visualizing the entirety of 
blood flow within the small joints than 2D cross sectional imaging and also that it 
may improve reliability of musculoskeletal ultrasound [122].  
The advent of 3D power Doppler ultrasound has begun a new era in tissue and 
organ vascularization research [135]. Using this technique, we can now assess a 
virtually reconstructed vascular tree within a volume of interest and can determine its 
vascularization by calculating indices using GE Medical Systems VOCAL software. 
These indices comprise the vascularization index (VI), flow index (FI) and 
vascularization flow index (VFI) and are thought to reflect the number of vessels 
within the volume of interest (VI), the intensity of flow at the time of the 3D sweep 
(FI), and both blood flow and vascularization (VFI). In-vivo studies have shown that 
VI correlates positively with microvessel density count as assessed by 
immunohistochemical techniques [136]. While there is very little literature available 
with regard to the use of 3D musculoskeletal ultrasound in rheumatological clinical 
practice, it has been well researched and utilised within the field of obstetrics and 
gynaecology and has proved to be highly reproducible between observers. Within 
the rheumatological field, one previous study showed good inter-observer agreement 
between 3D PDUS scores	  in twenty-four patients with active arthritis and first-time 
treatment with the TNF-α inhibitor adalimumab but showed no significant 
improvement in reliability compared to 2D scores [126]. However this study 
employed a manual sweep of the probe where the transducer was mechanically 
moved in one direction from medial to lateral over the dorsal side of the joint (free-
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hand sweep) to obtain a sequence of 15 2D PDUS images. In our experience the 
free-hand sweep generates a large amount of artefactual PD signal and poorer 
quality images which make calculating PD volume within the joint space less reliable 
than the automated sweep we used. In our study, the process of acquisition in 3D 
US was automated, requiring only a few seconds per small joint and can be 
performed by a relatively unskilled operator, whereas in general, 2D scanning takes 
more time per scan and more training to obtain optimal images. Certainly in our 
study both inter- and intra-observer reliability was excellent despite only limited 
training of the second user. Ideally however, reliability of both acquisition of the 
images as well as reading of stored images should have been measured as in some 
studies the greatest variability in results lies with image acquisition rather than 
reading images [90,113]; unfortunately, time constraints did not make these 
measures possible in our study. 
 
In this thesis, I have demonstrated the utility of power Doppler ultrasonography as a 
marker for prognosis in patients with early rheumatoid arthritis. In addition, we have 
used the data obtained in this study to develop two exploratory equations which 
estimate structural damage in biologic-naïve patients with early RA over 12 months, 
using several easily recorded baseline variables. The uniqueness of our models are 
in the inclusion of baseline ultrasound data, in particular the volume of vascularised 
synovium by power Doppler found at the MCP joints which has not been described 
previously. Vastaesaeger et al have previously developed a risk matrix model for the 
prediction of RA patients with rapid radiographic progression, however the potential 
contribution from imaging was not assessed [123]. As described above, the 
125	  
	  
longitudinal study by Filer et al demonstrated that grey scale and power Doppler 
scanning of the metacarpal, wrist and metatarsal joints provided the optimum 
ultrasound data to improve on clinical predictive models for the development of RA 
from early undifferentiated inflammatory arthritis, with power Doppler variables 
performing better than grey scale variables with a uniquely high specificity for RA 
compared with other groups of patients. These data are compatible with data from 
Freeston et al who found that the presence of power Doppler had good sensitivity 
and specificity for persistence of inflammatory arthritis in a mixed population of 
patients with early inflammatory symptoms [124], and with data demonstrating the 
importance of a negative PD signal and its association with stable remission. 
Our analysis suggests that synovial vascularity as demonstrated by power Doppler 
ultrasonography and in particular 3D Power Doppler Volume is of use in predicting 
progression of erosions and cartilage loss in RA with implications for its contribution 
to the pathology of structural damage. It has potential to be used, in conjunction with 
demographic data, to inform decisions on whether anti-TNFα or other biologic 
treatment should be deployed immediately for RA patients. 
 Our data are in line with previous findings of ultrasonographic power Doppler signal 
as an independent predictor of structural damage in early RA, which we have 
defined by two different imaging modalities – conventional radiograph and 
ultrasound. Structural damage on ultrasound as seen in our study is likely to an 
under representation of true damage because of the technical limitations of erosion 
detection by ultrasound as described above. In addition because of time restraints 
during the study, we did not examine the volar surface of the MCP joints for erosions 
(however this is less likely to have an impact on the results as it has been estimated 
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that only 2% of erosions occur at this aspect [101]) nor did we examine the wrists or 
MTP joints for erosive change or vascular signal which have been shown to be 
involved in the majority of patients with RA. Despite this, at baseline we still detected 
twice as many erosions at the MCP joints on ultrasound compared to radiograph 
which rose to approximately four times as many by 12 months with a significant 
correlation to baseline vascular signal. 
In addition, for the first time we have studied the utility of 3D imaging and power 
Doppler volume in a clinical setting using novel methods for analysis of volumetric 
data within the MCP joints. These methods have not previously been used within a 
clinical nor research setting and were derived during the course of our study 
specifically to calculate volumetric data within the MCP joint reliably and accurately. 
Our results show that this modality potentially has greater predictive power than 2D 
imaging with excellent reliability, and in time, automated volume calculation may 
make this modality easier to use in a clinical setting. We have combined these data 
in two equations with high specificity for predicting which patients will experience 
severe deterioration over a year while on conventional DMARDS, and would thus 
benefit from early use of biologic therapy. While vascular signal seen on ultrasound 
has previously been described to predict which patients would remain on anti-TNF 
therapy after one year [118], this is the first time that it has found clinical utility in 
predicting which patients would derive clinical benefit in the early use of biologics 
therapy. 
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4.2 Future Direction 
Further analysis of the data collected during this study could be conducted to inform: 
• Whether the conclusions are sensitive to what might have happened among 
the 9 patients who were lost to follow-up or otherwise failed to complete the 
study. 
• The predictive value of the models in estimating change in VdH and erosions 
scores for the six patients who dropped out of the study because they were 
transferred to anti-TNFα treatment before the study was completed, 
Future study could be conducted to inform: 
• Whether the models suggested by the results of this study stand up to repeat 
analysis under the same conditions. 
• Whether a more comprehensive set of biomarkers can be used to further 
inform the prediction of future deterioration (howsoever measured) in a larger 
sample of patients. 
• In addition it would be informative to further investigate the predictive power of 
baseline imaging in predicting progression of structural damage in patients 
with RA, by a direct comparison between MRI and ultrasound imaging. Some 
authors argue that bone oedema (osteitis) seen on MR imaging is the most 
powerful predictor of future joint erosion [136]. However studies comparing 
the two modalities directly are not numerous, and those that exist seem to 
show that baseline PD signal was more predictive of structural deterioration. 
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Table 4.1 Studies investigating prediction of progression of joint erosions in 
patients with rheumatoid arthritis (RA) using baseline imaging parameters. 
From: McQueen.F;	  Ann Rheum Dis 2011;70:241–244 
 
The studies conducted thus far include patient participants numbering from the tens 
to several hundred. For a more definitive answer as to which modality has greater 
predictive ability, a large prospective multicentre comparative study, whereby each 
modality is optimized technically (as discussed previously), comprising ideally 
several thousand patients would be useful.  
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